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Delivering drugs to the eye can be challenging due to complex anatomy and 
unique physiology of the eye. In order to treat ophthalmic diseases effectively, we must 
consider both effectiveness of the drug and the delivery method. This is because 
regardless of pharmacological therapies, complex ocular anatomy might prevent 
penetration of the drug to the targeted location, which will reduce the efficiency of the 
pharmacotherapies. 
This work introduces novel approaches to enhance targeting of pharmacotherapies 
to cornea, ciliary body, choroid, and posterior segment of the eye using microneedles as a 
drug delivery platform. The highly targeted drug delivery method using microneedles 
provides many advantages: (i) bioavailability approaches 100% by delivering drugs 
directly to the targeted tissue, (ii) side effects are reduced due to lower dosage 
requirement by delivering more drugs to the targeted site, (iii) patient compliance can be 
improved by administering longer controlled-release formulations which is not possible 
without highly targeted delivery, (iv) all these can be done in a minimally invasive way 
using microneedles. Research presented here involves utilizing microneedles as a device 
and novel pharmaceutical formulations to enhance targeting ability of drugs. 
First part of the work determines the ability to deliver protein therapeutics into the 
cornea using coated microneedles to suppress corneal neovascularization in an injury-
induced rabbit model. The results show that we were able to coat and deliver a protein 
therapeutic (bevacizumab) locally into the intracorneal space of the cornea in a minimally 
invasive way and demonstrated that this approach could be effective to suppress 
 xxii 
neovascularization after suture-induced injury using a much lower dose compared to 
other conventionally used methods. The data show that highly targeted delivery of the 
protein therapeutic gave a better biological response with 11,000 times less dosage 
compared to topical administration. 
The second part of the research aims to develop novel formulations to target 
ciliary body and choroid via suprachoroidal space injection. In this study, we develop 
novel polymeric excipient formulations that immobilize injected polymeric particles to 
target ciliary body or to enhance mobility of polymeric particles to target entire layer of 
the choroid. The results show that a strongly non-Newtonian fluid can be used to 
immobilize the particles at the injection site up to 2 months. The results also show that 
high molecular weight formulation with weakly non-Newtonian fluid can be used to 
increase the spreading of particles away from the injection site and are able to reach 
100% coverage of the choroidal surface with a single injection.   
The third part of the research aims to determine the biological response of 
targeting anti-glaucoma therapeutics to the ciliary body in rabbit model. The targeting of 
ciliary body was achieved via injection into the supraciliary space, the anterior part of the 
suprachoroidal space. This represents the first study to target anti-glaucoma therapies to 
the ciliary body and compares them to the topical delivery. The results show we can 
achieve 500 – 1000-fold dose sparing of two major classes of anti-glaucoma drugs by 
targeted delivery via supraciliary space injection.  
The fourth and last part of the research aims to develop novel emulsion droplets to 
target different locations within the eye using gravity-mediated delivery technique via 
suprachoroidal space injection. This work demonstrates nanoparticles can be used to 
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stabilize the emulsion droplets and to enhance targeting ability within the eye. The results 
show that particle-stabilized emulsion droplets of a high-density emulsion can create 
movement inside the suprachoroidal space in the direction of gravity. Consequently, by 
simply changing the orientation of the eye, we can deliver nanoparticles preferentially 
towards the front or the back of the eye.  
Overall this work demonstrates that microneedles have the capability to deliver 
pharmacotherapies to cornea, ciliary body, choroid, and posterior of the eye in a highly 
targeted manner and provide significant dose sparing in the rabbit model. Delivery can be 
done in a minimally invasive way to deliver polymeric particles in a highly targeted 
manner that is much better than currently used methods. This work represents the first 
study to specifically target specific locations in the eye by using novel formulations and 
delivery methods. The highly targeted delivery method can reduce the side effects due to 
low dosage requirement by delivering more drugs to the targeting site. This low dosage 
requirement will allow us to improve patient compliance by formulating longer 
controlled-release formulations for targeted administration in a simple, reliable, and in a 












Ocular diseases affect many people worldwide.  It is estimated about 80 million 
people worldwide are visually impaired or disabled, and the number of patients increases 
approximately 7 million people per year.  In United States alone, about 3.4 million people 
over the age of 40 are blind or visually impaired [1, 2]. Many ocular diseases can lead to 
blindness and are preventable if managed correctly. However, current ophthalmic drug 
delivery is constrained by the complex anatomy of the eye, which prevents easy 
penetration of drugs.  
Most often used methods to deliver drugs to both anterior and posterior of the 
eyes in clinic are topical, intravitreal, and periocular administrations. Topical delivery is 
the mainstay to deliver drugs to the anterior segment but only acts transiently. Ocular 
barriers such as tear fluid, corneal epithelium, and conjunctiva only allow small amount 
of applied drugs into the eye. Low penetration of the drug forces patients to follow 
stringent dosage regimens, which reduces patient compliance [3, 4].  
There are limited options for delivering drugs to their targets in the posterior 
segment of the eye. The periocular administration delivers drugs on the outer surface of 
the eye for it to diffuse into the eye. Periocular method offers minimal tissue damage but 
suffers from low targeting efficiency. The intravitreal injection involves administering 
the drug formulation directly into the center of the eye for it to diffuse outward towards 
choroid and retina. The intravitreal route is an invasive way to deliver drugs and often 
carries risk of ocular infections. 
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Conventional methods are not targeted to the pharmacological site of action 
effectively. Hence, there is great need for novel delivery strategies for eyes. The effective 
drug delivery system should be (i) minimally invasive, (ii) safe, and (iii) selctively 
targeted. Minimal invasiveness reduces any damage to the ocular tissue, possible 
infections and pain associated with delivery, which increases patient compliance. Highly 
targeted drug delivery method allows significant amount of dose sparing by having high 
amount of drug at the targeting site and also reduces possible side effects. Due to low 
penetration of the many ophthalmic drugs, it is often impossible to deliver long-term 
controlled release formulation. Significant dose sparing will allow us to formulate 
controlled release formulation, which would not be possible without highly targeted 
delivery method. 
Using previously developed microneedles based ophthalmic drug delivery method 
as a tool, the research presented here demonstrates the capabilities to deliver 
macromolecules in vivo and develop novel formulations to enhance targeting ability 
within the eye. More specifically, we aim to develop highly targeted approaches to 
deliver drugs to cornea, ciliary body, choroid, and back of the eye. Overall objectives of 
this research are to (i) demonstrate the effectiveness of coated microneedles to deliver 
protein therapeutics into cornea in the injury-induced neovascularization animal model, 
(ii) develop formulations to target polymeric particles to ciliary body and choroid using 
polymeric excipient formulations, (iii) demonstrate the effectiveness of ciliary body 
targeting in glaucoma animal model, and (iv) develop an effective formulation to target 
polymeric particles to back of the eye using high-density particle-stabilized emulsion 
droplets.  
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2  BACKGROUND 
 
2.1. Anatomy of the Eye 
The human eye is spherical in shape but slightly flattened in the anteroposterior 
direction with diameter of 23-24 mm [5]. The inner portion of the eye, between lens and 
retina, is filled with gelatinous fluid called vitreous humor. The outer layer of the eye, 
which surrounds the vitreous, is comprised of three layers. The outermost layer is the 
sclera, the middle is the choroid and the inner layer is the retina.  The anterior portion of 
the eye consists of cornea, ciliary body, iris, aqueous humor and lens. The aqueous humor 
is the fluid inside the anterior chamber that is produced by the ciliary body. The aqueous 
humor travels around the iris and it drains into trabecular meshwork.   
The thin, transparent mucous membrane that lines the inner surface of eyelids is 
the conjunctiva. The conjunctiva starts at the limbus and continues to the inner surface of 
the eyelid that covers anterior portion of the eye. The conjunctiva also helps lubricate 
eyes by producing mucous. The conjunctiva is transparent, but it contains many small 
blood vessels. Conjunctivitis, commonly known as red eye, is characterized by 
inflammation of these small vessels. Since the conjunctiva is exposed to external 





Figure 2.2.1.1 Anatomy of the human eye (copied from www.nei.hih.gov) 
 
The clear transparent portion of the eye is the cornea. The cornea is a thin, 
concave tissue layer bathed on the posterior surface by the aqueous humor and abuts air 
on the anterior side across a thin tear film.  The thickness of human cornea, at central 
region, is about 0.52 mm to 0.67 mm [5]. The corneal structure can be largely divided 
into three distinctive layers, which are epithelium, stroma and endothelium, respectively 
from anterior to posterior.   
The corneal endothelium consists of regularly arranged polygonal cells that do not 
regenerate themselves. Thus, the human corneal endothelial cell density decreases with 
age and the cells stretch to compensate for dead cells. The endothelium is responsible for 
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regulating fluids and transporting solutes between the aqueous humor and the cornea.  
The corneal endothelium plays a very important role in maintaining corneal transparency.  
The endothelium actively pumps fluid out the cornea to the aqueous humor. This 
maintenance of fluid volume inside the cornea is required for its transparency [6]. 
 
 
Figure 2.2.1.2 Anatomy of the cornea. (Copied from www.nei.hih.gov) 
 
The corneal stroma is comprised of over 90 percent of the thickness of cornea. 
The stroma is predominately comprised of extracellular matrix that is made of lamellar 
structure of collagen fibers that run parallel to surface of the cornea. This alignment of 
collagen fibers is important for the cornea to stay transparent.  The stroma is composed of 
200 – 250 lamellae of collagen fibers and they stretch from one side of limbus to the 
other [6]. Fibroblasts are the cells that can form collagen fibers, and keratocytes.  
Fibroblasts contribute to corneal healing and they are present throughout the stroma [7]. 
The corneal epithelium is the outermost layer of the cornea that is stratified, non-
keratinized, squamous epithelium.  The epithelium has five to seven cells with three 
forms of cells: two layers of flattened epithelial cells, two or three layers of polygonal 
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cells, and a single internal layer of basal cells [7]. The squamous cells at the surface of 
cornea are constantly shed off from abrasion caused by eyelids. The basal cells of the 
cornea undergo mitosis and the daughter cells move toward the surface of the cornea and 
begin to differentiate. This movement of the cell takes about 7 days [6]. The corneal 
epithelium is one of the fastest healing tissues in the human body. 
The sclera, the white portion of the eye, is a continuation of the corneal stroma.  
The sclera is composed of about 70 percent water that is primarily supported by collagen 
fibers.  Collagen fibers provide the structural integrity and shape of the sclera and the eye. 
Although the sclera is composed of the same material as corneal stroma, the sclera is 
nearly opaque because of the irregular arrangements of the collagen fibers [6]. 
The choroid is a vascular layer that lies between the retina and the sclera that 
provides oxygen and other nutrients only to the outer layers of the retina. Along with 
ciliary body and iris, the choroid forms uveal track. The retinal and uveal circulations are 
two different types of blood circulation in the eye. Uveal circulation supplies nutrients to 
the uvea, and outer and middle layer of the retina. On the other hand, retinal circulation 
supplies nutrients to the inner layer of retina [6]. 
The retina is the light sensitive tissue layer that is located at the most inner layer 
of the eye.  When light strikes the retina it starts cascade of events that sends signals to 
the various parts of the brain through the optic nerve. The retina is comprised of complex 
layers of neurons that are interconnected by synapses. There are only two kinds of 
neurons that are directly sensitive to the light; they are the photoreceptors. The three 
types of photoreceptors are the rods, cones, and intrinsically photosensitive retinal 
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ganglion cells, which are located at the inner layer of the retina. The retina is the only 
part of the central nervous system that is visible [6]. 
The Suprachoroidal space is a potential space in the eye that lies in between sclera 
and choroid. Suprachoroidal space is part of the uveoscleral outflow system that provides 
path for aqueous humor drainage [8]. The suprachroidal space becomes evident when an 
injection of fluid is made. During the injection, the suprachoroidal space rapidly expands 
to incorporate large amounts of fluid. Fluid injected in this area is drained from the eye 
rapidly. Supraciliary space is the anterior portion of the suprachoroidal space that lies just 
above the ciliary body of the eye. 
 
 
Figure 2.2.1.3. An image of the eye showing suprachoroidal space (indicated by blue 
line). The image was copied from www.NIH.gov 
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2.2. Eye Diseases 
2.2.1. Introduction 
Ocular diseases affect many people worldwide. It is estimated about 80 million 
people worldwide are visually impaired or disabled, and the number of patients increases 
approximately 7 million people per year. In United States alone, about 3.4 million people 
over the age of 40 are blind or visually impaired [1, 2]. Many ocular diseases can lead to 
blindness and are preventable if managed correctly. However, current ophthalmic drug 
delivery is constrained by the complex anatomy of eye, which prevents easy penetration 
of drugs. Moreover, low penetration of drugs requires patients to closely follow strenuous 
dosage regimens, which reduces patient compliance [3, 4]. Below is summary of diseases 
that are relevant to the research presented in this paper. 
 
2.2.2. Corneal Neovascularization  
Corneal neovascularization is excess growth of blood vessels in the cornea, which 
originates from the vasculature in the conjunctiva at the corneal edge. The main causes of 
corneal neovascularization include oxygen deprivation and excessive damage to ocular 
tissue. This is the natural response of our body to provide necessary nutrients and oxygen 
to the damaged corneal tissue. Human cornea is avascular tissue because it needs to be 
transparent to allow passage of light for proper vision. Since the cornea is avascular, it 
needs to obtain oxygen from the air and anything that blocks this process will cause 
corneal neovascularization. As a result, the most common cause of corneal 
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neovacularization is contact lens wear. The prevalence of corneal neovascularization 
among contact lens wearers is as high as 30 percent more than non-contact lens wearers. 
Corneal neovascularization can block a patient’s vision and may cause pain, excessive 
tearing, light sensitivity and redness [9]. 
Neovascularization is a very complex process that requires many different 
extracellular factors and processes. Neovascularization process starts from the release of 
pro-angiogenic factors, such as vascular endothelial cell growth factor (VEGF), basic 
fibroblast growth factor (bFGF) and platelet derived growth factor (PDGF), by damaged 
cells in cornea. After this, several cascades of processes, such as extracellular matrix 
degradation and arteriogenesis, are triggered to form mature blood vessels. However, the 
exact mechanism, all the responsible biological factors, and receptors still remain to be 
elucidated [10, 11]. There have been many attempts to prevent neovascularization by 
inhibiting biological factors throughout the cascade of processes [12]. The most 
successful method was to prevent neovascularization by inhibiting pro-angiogenic factors 
[13]. 
Currently, Genentech is marketing bevacizumab (trade name of Avastin®), which 
inhibits vascular endothelial growth factor (VEGF). Bevacizumab is a humanized 
monoclonal antibody that binds to VEGF that has molecular weight of 125 kDa.  United 
States Food and Drug Administration (FDA) first approved Bevacizumab in 2004 for use 
in metastatic colon cancer [14]. Since then, bevacizumab gained substantial interest in 
ophthalmology.  As of August 2010, over 500 articles have been published related to use 
of anti-VEGF drug in the eye. Since bevacizumab is a monoclonal antibody that binds to 
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VEGF to stop the vessel growth at the initial stage of the long process, this drug is known 
to be very effective in preventing ocular neovascularization [11, 12]. 
More recently (2011), FDA approved a new anti-VEGF therapy, VEGF-Trap, 
which binds to more angiogenic factors: VEGF-A, VEGF-B, and placental growth factor 
(PIGF). It was designed to bind to all isoforms of VEGF, as opposed to pegaptanib which 
binds to only VEGF165. Afibercept is a recombinant fusion protein consisting of a portion 
of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human 
IgG1 formulated for intravitreal administration. It is known to have stronger binding 
affinity to VEGF compared to ranibizumab or bevacizumab [15]. Clinical trial for the 
VEGF-Trap showed that injection every 2 months produced similar efficacy and safety 
outcomes as monthly ranibizumab [16].  
Corneal transport is the most common tissue transplant, with 40,000 corneal 
transplants per year in the United States and 65,000 worldwide [17, 18]. Absent 
complications, corneal transplants are extremely successful and can be permanent cures 
for blindness [17]. However in 22% of transplants, there is a foreign body reaction to the 
sutures used to secure the transplant, which leads to blood vessel in-growth from the 
conjunctiva across the limbus and into the normally avascular cornea [19]. Despite 
conventional therapy with topical steroids or experimental therapy with topical or 
subconjunctiaval anti-VEGF antibody (ranibizumab, bevacizumab), this corneal 
neovascularization leads to transplant failure that requires removal of the transplant 15% 
of the time [19]. This is believed to be because steroids are not effective enough and the 
antibody, as a large protein, cannot be easily delivered to the site of action in the cornea.  
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2.2.3. Glaucoma  
Glaucoma is the second leading cause of blindness worldwide and is also the first 
leading cause among African Americans. Glaucoma is a non-curable disease. It is 
estimated that 4 million Americans have glaucoma but only about half of them know that 
they have it. There are 80,000 people who are already blind in America due to this 








Glaucoma causes optic nerve damage due to an increase in intraocular pressure.  
An increase in intraocular pressure can lead to permanent visual field loss. The visual 
field loss tends to occur very slowly from the peripheral side of the vision.  Thus, many 
of the patients do not realize their gradual vision loss. However, if the condition is 
detected at an early stage, it is possible to arrest or slow down the progression of disease 
with medication. The rise in intraocular pressure occurs when there is increase in aqueous 
production or a decrease in the outflow of the aqueous humor. The aqueous humor is a 
fluid in the anterior portion of eyes that bathes the ocular lens. This fluid flow provides 
nutrients for avascular ocular tissue, such as the cornea and the lens. If there is an 
imbalance of production or drainage of the aqueous humor, intraocular pressure can be 
elevated.  This elevated pressure, which is believed to push the optic nerve at the back of 
the eye against the rigid structure of sclera, causing the death of retinal cells.  The two 
main types of glaucoma drugs target either aqueous production (ciliary body) or outflow 
(trabecular meshwork). Most glaucoma medication requires patients to follow a strict 
regimen that is often 3-4 times a day. If medication cannot control the flow of aqueous 
flow, surgical procedure is necessary to control intraocular pressure [3]. 
Patient compliance with glaucoma medication is a major problem in preventing 
blindness. It is estimated that 50 percent of patients failed to refill their prescription the 
first time and 25 percent of them failed to refill their prescription the second time. This 
low patient compliance comes from gradual peripheral vision loss and stringent dosage 
regimens. It is estimated that out of 4 million Americans who have glaucoma, only half 
of people know that they have it. Even if the patient is aware of this disease, low 
absorption of ophthalmic drugs into the eye requires patients to apply the drug multiple 
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times a day. This low patient compliance and bioavailability of glaucoma drugs creates 
need for a better delivery method [3]. 
 
2.2.4. Age-related Macular Degeneration 
Age-related macular degeneration (AMD) is a disease that affects older 
generation and results in a vision loss due to damage in central part of the retina called 
the macula. AMD is the third leading cause of blindness. It is estimated that more than 
1.8 million individuals in United States are afflicted by wet AMD and that number is 
expected to grow to almost 3 million by 2020 [21, 22]. 
The dry (non-exudative) form of AMD is characterized by accumulation of 
cellular debris between choroid and retina called drusen, which causes progressive death 
of retinal cells. Unfortunately, there is no pharmacological therapy available for the dry 
form of AMD so far [23]. The wet form (exudative) is more severe case of AMD and is 
caused by choroidal neovascularization (CNV); abnormal blood vessels grow in choroid. 
Although the AMD is characterized by death of the retinal cells, the underlying problem 
lies in choroid. 
CNV can be further categorized as “classic” or  
“occult” based on fluorescein angiography. In “occult”, new vessels are generally found 
in choroid, whereas in “classic” CNV vessels break through the RPE and enter the sub-
retinal space [24, 25]. Despite the pathophysiological differences in “classic” and “occult” 
CNV, there are no distinctions in treatments made between classic and occult choroidal 
neovascularization. 
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Pharmacological therapies involve use of drugs, such as anti-angiogenesis drugs, 
and steroids [26-28]. Only within the past decade, many revolutionary therapeutic agents 
became available to effectively manage chorioretinal diseases [29, 30]. Macugen® was 
the first anti-VEGF drug that was approved for intravitreal injection for treatment for 
AMD. Macugen® acts by binding specifically to the VEGF165, a protein that plays 
critical role in angiogenesis. Clinical trial showed significant effectiveness in preventing 
further vision loss [27]. Largely successful ranibizumab or Lucentis®, an anti-VEGF 
drug, which was approved in 2006, followed Macugen®. Ranibizumab is a monoclonal 
antibody fragment derived from the bevacizumab, a whole IgG molecule. Bevecizumab 
(Avastin®) had been approved earlier than ranibizumab, but there was a concern with its 
capability to diffuse into the retina due to its large size. Therefore, this triggered the 
development of a ranibizumab in order to resolve this issue [28]. 
The main method to deliver anti-VEGF molecules is an intravitreal injection. It is 
thought to be intravitreal delivery of anti-VEGF is more effective with the patient with 
classic CNV compared to occult CNV [31-33]. This is because compromised RPE and 
retinal layer allows better penetration in classic CNV, whereas, intact RPE and retinal 
layer prevents easy penetration of the molecules to the choroid in occult CNV. However, 
there are no clinically used methods to deliver therapeutics to the targeting tissue layer to 
obtain best treatment efficacy.  
 
2.2.5. Diabetic Retinopathy 
Diabetic retinopathy caused by complication of diabetes damages to the retina. 
Fluctuations of the sugar levels cause microvascular complication in the blood vessels in 
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the retina. The prevalence of diabetic retinopathy increases with duration of diabetes, and 
nearly all persons with type I diabetes and more than 70-90% of those with type II have 
some retinopathy after 20 years [34, 35]. Diabetic retinopathy can be classified into two 
stages namely non-proliferative and proliferative. Non-proliferative diabetic retinopathy 
is characterized by retinal hemorrhages or leakages of the vessels. Proliferative diabetic 
retinopathy occurs with further retinal ischemia and is characterized by growth of new 
blood vessels on the surface of the retina or the optic disc. 
Treatments for the advanced stage of diabetic retinopathy involve the use of laser 
therapy or a surgical procedure called vitrectomy. For early stage diabetic retinopathy, 
available pharmacological treatments are use of anti-angiogenics, steroids, and 
neuroprotectants. However, conventional delivery methods suffer from poor targeting 
ability to the site of action. Therefore, more effective and improved delivery methods of 
the medications could prevent patients from moving into more advanced stages.  
For instance, intravitreal injection is pharmacological treatment that requires once 
a month injection into the vitreous body of the eye for six months or more if necessary. It 
requires follow up and maintenance to control the outcome of the disease. A highly 
targeted method of delivery would allow high level of drug concentration at the targeting 
site that could give significant dose sparing [26, 36, 37]. This would allow flexibility in 
dosing regimen that could deliver long term controlled release formulation.  
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2.3. Ocular Drug Delivery Methods 
2.3.1. Systemic 
Drug delivery into the eye poses significant challenges due to complex anatomy 
and unique physiology of the eye. Systemic (parenteral) administration could be used to 
target molecules to the places to overcome inefficiencies of the topical delivery. However, 
this non-targeted method requires high dosage to deliver therapeutic drug concentration. 
Following systemic administration, the blood-aqueous barrier and blood-retinal barrier 
are the major barriers for the systemic administration [38].  Both layers express tight 
junctions that prevent the drugs from penetrating into the eye [39]. 
A drug administered could reach the anterior segment of the eye via blood vessels 
in ciliary body. Drug can then diffuse from the iris into the aqueous humor. Access to the 
posterior segment via systemic administration is severely limited by blood-retinal barrier 
[38] as mentioned earlier. Lipophilic compounds have more ability to move across the 
blood-retinal barriers compared to hydrophilic compounds via passive cellular diffusion 
[40]. However, hydrophilic compounds have very slim chance of penetrating into the 
blood-retinal barrier [40]. 
 
2.3.2. Oral Delivery 
Oral delivery was studied as a possible noninvasive method to deliver drugs 
systemically however, it has been shown that limited penetration into the targeting tissue 
and systemic side effects are associated with oral delivery [41]. Furthermore, very limited 
compounds were investigated as oral medications for ocular diseases.  These compounds 
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only include analgesics, antibiotics, and antiviral agents [42-44]. The major prerequisites 
for the oral delivery is the high dosage to increase the bioavailability, which will 
inevitably increase side effects. 
 
2.3.3. Extraocular approaches 
2.3.3.1 Topical delivery 
Topical eye drops are a classical and predominant method to deliver drugs to the 
anterior portion of the eye.  Topical application is used often because of its noninvasive 
nature, ease of self-administration, and accessibility to the surface of eyes.  However, it is 
limited by very low drug bioavailability due to rapid clearance by tear drainage, 
absorption into vasculature, and poor absorption into the corneal epithelium. It is 
estimated that 75 percent of the applied dose is lost almost instantly through nasolacrimal 
drainage with topical eye drops. This high turnover rate of tears lowers absorption of 
drugs through ocular tissue.  For a small molecular weight drug, the bioavailability for 
the anterior segment of the eye is about 5 percent or less of topically applied drugs.  And 
for large molecular weight drugs, the bioavailability for the anterior segment of the eye is 
far less than 1 percent of topically applied drugs [45-47]. 
The foremost barrier that prevents topically applied drug from penetrating into 
inner components of the eye is the tear fluid. Tear film has two very efficient ways to 
protect our eyes from foreign substances. Tear fluid is composed of dual layers, top film 
is an aqueous layer and the bottom film is a mucin layer.  The first barrier property of 
tears is rapid drainage of tear fluid.  Baseline and reflex blinking of the eye causes rapid 
drainage of tear fluid, which quickly removes any noxious agents [6]. The second barrier 
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property of tear film is adhesion of foreign particles to the mucin layer.  The mucin layer 
of tear film adheres to foreign particles and prevents them from reaching the surface of 
cornea. These two properties of tear film prevent noxious substances from penetrating 
into the cornea.  However, this can also act as a disadvantage because it also prevents the 
penetration of topically applied drugs [48].   
Tear film is not the only barrier that prevents topically applied drugs to penetrate the 
inner components of the eye.  Other barriers are the cornea and the conjunctiva.  Any 
amount of drug that is able to remain in tear film must diffuse across the cornea or 
conjunctiva to reach its target.  The cornea is, however, a trilaminar structure that blocks 
the penetration of drugs.  The three layers are the epithelium, stroma, and endothelium.  
The epithelium, a hydrophobic layer, has very tight junctions around the cells that 
effectively blocks the penetration of both large and hydrophilic compounds. The stroma, 
a hydrophilic layer, prevents penetration of hydrophobic compounds. Furthermore, even 
if an applied drug gets absorbed into conjunctiva, the drug gets removed by the 
conjunctival capillaries. The combination of these two barriers results in very low 
bioavailability for topically applied drugs.  It is generally considered that less than five 
percent of the topically applied small molecular weight drugs penetrate into the ocular 
tissue. Current research in topical drug delivery is aimed at prolonging the residence time 
of the drug in the cul-de-sac to increase the penetration [49, 50]. 
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2.3.3.2 Periocular Administration 
	  
Figure 2.3.3.1. Various different location of periocular injection. Copied from Raghava 
et al [51]. 
 
Periocular injection refers to injection around the peripheral tissue of eyes.  
Different types of periocular injections include the subconjunctival, sub-tenon, peribulbar, 
retrobulbar, posterior juxtascleral, inferior rectus muscle and superior rectus.  Periocular 
injection is used when large quantities, i.e., hundreds of microliters, of drugs need to be 
delivered.  Most of the topically applied drugs will not reach posterior segment of the eye.  
If the drug needs to be delivered to the back of the eye, periocular injection can be used.   
Periocular injection provides a great efficacy advantage over traditional topical eye drops 
for delivering drugs to posterior segment of the eye, but has other limitations.   
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The periocular injections, such as subconjuctival injection, could be used for 
delivering drugs to the anterior portion of the eye. Subconjuctival drug delivery has 
limitations for delivering drugs to the anterior portion of the eye, such as glaucoma and 
corneal neovascularization. The main drawback of subconjunctival injection is rapid 
clearance of injected drugs into systemic circulation.  The subconjunctival space is full of 
capillary blood vessels that clear injected drug quickly. In addition to this, injected drugs 
must diffuse across the sclera and the choroid to reach the inner part of the eye.  Since a 
large portion of drugs injected into subconjuctival space gets absorbed into systemic 
circulation, it may bring side effects due to its non-localized delivery method [51].	  
 
2.3.4. Intraocular delivery 
2.3.4.1 Intravitreal Administration 
Currently, drugs are delivered to treat diseases of the choroid and retina by 
intravitreal administration. This is commonly done by injecting a liquid formulation into 
the vitreous, which is not the pharmacological target. Intravitreal injection was first 
reported in 1911 by Ohm [52] as a method to introduce air into the vitreous for a 
treatment for retinal detachment. In mid-1940s pharmaceutical administration, penicillin, 
was first introduced for treatment for endophthalmitis. However, the treatment was often 
delayed until the infections became worse, which made the treatment unsuccessful. This 
prevented the adaptation of the treatment until 1970s. New antimicrobial agents, 
combined with the poor success of alternatively available treatment of endophthalmitis 
led to renewed interest in intravitreal injection [53] and followed by successful treatment 
of endophthalmitis in human patients [54]. In 1980s, there was increase in adaptation of 
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the intravitreal injection for other pharmacological therapies. Finally in 1998, FDA 
approved an intravitreal injection of antisense compound used to treat retinitis [55]. The 
gradually increasing confidence in the safety of intreavitreal injection led to widespread 
us of injection techniques. In early 2000s, vascular endothelial growth factor inhibitors 
ranibizumab [56], and pegaptanib sodium [57] for the treatment of neovascular age-
related macular degeneration was approved by FDA. The injection procedure only 
requires the local anesthesia and is performed with 27 or 30 gauge needle approximately 
3 mm away from the limbus.  And the injection volume ranges from 20-100 µl [58].  
Intravitreal injection is an invasive procedure that requires a large needle to 
penetrate across the whole layer of the eye, therefore, some associated complications are 
inevitable. Possible complications include endophthalmitis, retinal detachments, iritis, 
uveitis, intraocular hemorrhage, cataract, and hypotony, which could be caused by either 
injection procedure or injected drug. The prevalence of endophthalmitis is estimated to be 
0.3% per injection and 0.9% per eye [58]. If these complications arise, it could lead to 
permanent vision loss [58].  Although repeated injections potentially increase the rate of 
complications, it is not uncommon to have intravitreal injection at monthly basis. 
Therefore, novel delivery method that can deliver long term controlled release 
formulation could significantly improve complications caused by repeated injections. 
 
2.3.4.2 Intravitreal Implants 
Increased risk related with intravitreal administration prompted an effort to reduce 
possible complications of repeated intravitreal injections. There are numerous products in 
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markets that are capable of releasing drug into the vitreous for up to 3 years for non-
biodegradable implants and up to 6 months for biodegradable implants.   
Many of implants are placed directly in the vitreous or attached to the globe for 
the drug formulation to release into the vitreous [59]. While all of the non-biodegradable 
implants require removal of the implants once the implant fully releases the drug [60], 
biodegradable polymeric drug delivery system poses promise for the treatment of ocular 
diseases. 
 
2.3.4.3 Suprachoroidal delivery 
In previous research, researchers had used invasive surgical methods and 
catheters [61-65], in order to access the suprachoroidal space.  However, these methods 
required surgical incision of the sclera and insertion of the long cannula towards the 
posterior site before formulation was injected into the suprachoroidal space [63].  
Microneedles’ microscopic size makes it possible to deliver materials into 
suprachoroidal space without complex surgical procedures. Microneedle allows precise 
placement of the needle tip right at the suprachoroidal space. In addition, microneedles 
have been shown to inject fluid into suprachoroidal space in rabbit, pig, and human eyes 
in a minimally invasive way [66] compared to existing methods. Since suprachoroidal 
space is right above the choroidal blood bed, delivered drugs in this region tends to be 
cleared out fast [65]. Therefore, controlled release formulation becomes a desired method 
to deliver drugs efficiently when the drugs are injected into suprachoroidal space.  
Progress in this field, however, has been limited by the poorly targeted ability of 
suprachoroidal injection. Injected polymeric particles cover a portion of the 
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suprachoroidial space but not well targeted towards either anteriorly to ciliary body or 
posteriorly to the whole layer of the choroid. For example, a high pressure point at the 
back of the eye makes it hard for injected particles to penetrate towards the back of the 
human eyes [67]. Meanwhile, an anteriorly injected formulation quickly spreads away 
from the injection site when ciliary body is targeted [66-69].  
 
2.3.5. Density-driven drug delivery 
2.3.5.1 Introduction 
The idea of creating density differences to enhance drug delivery has been used 
before in creating floating particles to enhance gastric retention of drugs and pulmonary 
delivery [70-72]. Both approaches are similar in a sense that the key parameter that was 
considered was a density difference between particles and the carrier fluid to enhance 
delivery of drugs to the targeted site. 
 
2.3.5.2 Pulmonary drug delivery  
Delivering drugs to the lung by inhalation is very attractive due to highly 
permeable epithelium of the human lungs and can be easily accessible by inhaled dose 
[73]. Human lungs have very efficient ways to clear foreign materials. In the upper 
airways, mucosal layer will rapidly clear away the particles. In the deep lung, alveolar 
macrophages clear away soon after the deposition of the particles [74]. 
Conventional pulmonary controlled release particles have 10 to 20% 
bioavailability and are prone to rapid clearance by alveolar macrophages [71]. Normally 
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aerosol particles are in a range of 1- 3 µm diameter in an effort to increase the penetration 
into deep lungs [71]. However, the aerosol particles are still rapidly cleared away from 
the lung tissue by macrophages due to its small size. In order to address the issue, 
Edwards et al. [75] developed low-density porous, which enables significantly higher 
penetration rate into deep lung with large particle size (~7µm) by slowing down the 
clearance rate. 
 
2.3.5.3 Gastrointestinal drug delivery 
Periodic gastric empting creates the problem to orally ingested delivery of drugs 
to stomach. In an effort to prolong delivery of drugs to stomach, various floating dosage 
forms to the gastrointestinal tract were developed as early as 1978 by Sheth and 
Tossounian [76]. As the shell of the capsule dissolves, a gel with density less than gastric 
fluid is formed and this allows the capsule to float to increase the retention of tablets 
inside the stomach. After this, various oral delivery systems have been developed using 
many different techniques such as polymeric matrices [77], microcapsules [78], 
microparticles [79], and bioadhesives [80]. 
There are two main types of floating dosage forms: effervescent and non-
effervescent floating dosage forms. Effervescent dosage forms are formulated using 
various effervescent compounds such as sodium bicarbonate, tartaric acid, and citric acid. 
The contact with acidic gastric contents will liberate CO2, which become entrapped in 
swollen hydrocolloids providing buoyancy to the dosage forms. Studies showed that the 
gastric residence time was prolonged considerably (24 hours) compared to uncoated 
beads (1 to 3 hours) [81]. 
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Non-effervescent floating dosage forms use a gel forming or swellable cellulose 
type of hydrocolloids, polysaccharides, and matrix-forming polymers like polycarbonate, 
polyacrylate, polymethacrylate, and polystyrene [72]. Upon contact with gastric fluids, it 
attains the density of < 1.  The polymer matrix also serves as a reservoir and allows 
sustained release of drug through the gel.  
 
2.3.5.4 Particle stabilized emulsion (Pickering emulsion)   
The idea of stabilizing emulsion droplets using solid particles is named after S.U. 
Pickering, who described this phenomenon in 1907 [82]. Pickering recognized the role of 
solid particles in stabilizing emulsions. He also noticed that solid particles were wetted 
more by water than by oil and that acted as emulsifying agents for oil-in-water emulsion. 
Since then, many investigators have studied the stability of particle-stabilized emulsion 
droplets [83-85]. Due to this distinct characteristic, particle stabilized emulsion droplet 
had been studied in drug delivery applications [86]. Also, since particle stabilized 
emulsion droplets could be stabilized using particles such as silica, clays, titanium 
dioxide, latex and many others [87-90], this type of droplet is used in many industries, 
such as food industry, cosmetic industry, pharmaceutical industry, petroleum industry, 
and agricultural industry [83].  
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2.4. Microneedles in Drug Delivery 
2.4.1. Introduction 
Although idea of microneedles was first proposed in 1971, it was not popularized 
until 1990’s due to lack of required technology for microneedle production [91]. The 
initial application of microneedles was in the area of transdermal drug delivery. Also, the 
first published study of microneedles in transdermal drug delivery in 1998 triggered the 
emergence of many different types of microneedles [92, 93]. 
The concept behind microneedle usage is to create a pathway for drugs to 
penetrate across surface of the skin. Only a micron-sized needle is able to increase drug 
transport because the main barrier of the skin, stratum corneum, is about 10 to 20 micron 
in thickness. Due to this micron-sized needle, damage to the tissue and pain can be 
minimized, compared to conventional needles.  
The first in vivo test of microneedles in ocular drug delivery showed coated and 
hollow microneedles could be used to deliver drugs safely into the eyes. The major 
advantage of using microneedles compared to traditional topical eye drops is that 
microneedles avoid two of the major barriers of ophthalmic drug delivery, which are tear 
fluid and the corneal epithelium. Furthermore, micron sized tips allow highly localized 
delivery of drugs compared to traditional topical eye drops [94, 95]. 
Microneedles can provide an advantage over traditional methods by targeted drug 
delivery in a minimally invasive manner. Because the drug is directly delivered to the 
targeted site, dosage requirement can be minimized.  Minimal dosage can provide lower 
side effects and cost for patients.  In addition, targeted delivery shows higher efficacy of 
applied drugs compared to traditional methods. In contrast, most conventional ophthalmic 
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drugs cannot provide a controlled release device without invasive surgery because of the 
high dosage requirement. Therefore, microneedles can provide distinct advantages over 
conventional methods due to lower dosage requirements, ability of utilizing polymeric 
devices to achieve controlled release of drugs in longer period of time. 
 
2.4.2. Types of microneedles 
The types of microneedles include: solid, dissolvable, and hollow microneedles.  
The solid microneedles can be coated with drugs and then inserted into the targeted site. 
Dissolvable microneedles were developed and used to achieve controlled release of drugs 
into inserted tissue [93, 96]. Hollow microneedles, which contain a hollow bore, offer the 
possibility of transporting drugs through the interior of the needle by diffusion or 
pressure-driven flow. Since the first practical introduction of microneedles in 1998, the 
application has been mostly limited to transdermal drug delivery and limited amount of 
work has been done in other fields including ocular drug delivery.  
 
2.4.2.1 Solid microneedles 
Solid microneedles were designed to create micron-scale holes in the skin and the 
hole allows molecules to be transported more easily into the tissue. Solid microneedles 
can be fabricated using materials such as silicon and metal. Solid microneedles arrays 
were first made using silicon wafer and developed for intracellular delivery in vitro [97] 
and these needles were inserted into cells to enhance molecular uptake and gene 
transfection. Three years later after this in vitro study, another study to increase 
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transdermal drug delivery was conducted by Henry et al. [98]. In this study, the authors 
showed that the penetration of microneedles through the upper most layer of the skin 
(stratum corneum) created the direct pathways for molecules to diffuse into the skin. 
Furthermore, the follow-up study by McAllister et al [99] showed permeability of calcein, 
fluorescently-tagged bovine serum albumin (BSA), and nanospheres could be increased 
up to 10,000 fold using silicon microneedles. However this strategy requires two steps. 
First step is creation of microscopic pores and second step is application of the drug 
afterword, which makes the treatment to be more complicated. 
This strategy can be applied to the eye as well. Solid microneedles can be used to 
create microscopic pores across the cornea and sclera. Topical eye drops could then be 
applied to the conjunctival sack to enhance penetration of the drug into the ocular tissue. 
However, rapid clearance rate of topical delivery makes this method less attractive. In 
order to reduce this two-step process to one simple procedure, new approach was 
developed. This method involves coating drug formulation on the surface of the solid 
microneedles. After the insertion of the coated microneedle into the tissue, the 
formulation will rapidly dissolve off to deposit drugs directly into the targeting tissue. 
Inserted microneedles can then be removed right away leaving the coated drug in the 
tissue.  
Jiang et al published the first usage of coated microneedles in ocular drug delivery 
in 2007 [94]. Jiang and others demonstrated that coated microneedle could be used to 
deliver drugs into the eye via intracorneal route. Sodium fluorescein was coated and 
delivered into rabbit cornea using metal microneedles. Then the concentration of 
fluorescein was measured in cornea, aqueous humor and lens over time. The sodium 
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fluorescein concentration after 3 hours was approximately 60 times higher than a topical 
application of an equivalent dose. Similar study was also done using pilocarpine by Jiang 
et al. They showed similar constriction of the pupil with approximately 100 fold less does, 
compared to topical application. These experiments showed that a drug could be 
administered into cornea using microneedles and allow much larger amounts to be 
penetrated to the anterior segment of the eye compared to topical delivery. 
 
 
Figure 2.4.2.1. Microscopic image of a single solid miconeedle used for intracorneal 
drug delivery. Copied from Jiang et al [94].  
 
2.4.2.2 Dissolvable microneedles 
Alternative to inserting a microneedle, depositing the drug, and removing the 
microneedles, the drug-loaded microneedles itself could be left in the tissue. These 
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microneedles are usually made of biodegradable polymers that encapsulate a drug and as 
the polymer dissolves it releases the drug over time. The benefits of using dissolvable 
microneedles are that they do not produce sharp wastes, and offer sustained release of a 
loaded drug. Dissolvable microneedles have been fabricated using various materials such 
as poly lactic-co-glycolic acids (PLGA) [100], and carboxymethylcellulose (CMC) [101]. 
However, applications of the dissolvable microneedles were limited to transdermal drug 
delivery. Even though various compounds such as small molecules [102], proteins [103], 
and vaccines [104] were shown to deliver into the skin, dissolvable microneedles have 
not been tested in the eye so far. 
 
 
Figure 2.4.2.2. A carboxymethylcellulose/trehalose dissolving microneedle patch 
encapsulating human growth hormone. Adapted from Lee et al 2011 [103]. 
 
2.4.2.3 Hollow microneedles 
A limitation of coated microneedles is limited surface area that allows only small 
amount of drug to be delivered. In order to overcome this limitation, hollow microneedles 
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were developed. The fabrication of the hollow microneedles can be challenging because 
of the internal bore needs to be made within the structure of the needle. Many different 
materials, such as silicon, nickel, gold, and glass have been used to create hollow 
microneedles [105-107]. Glass microneedles were fabricated using micropipette-pulling 
techniques and were shown to deliver insulin into human skin in vivo [108]. Jiang et al. 
published first usage in hollow microneedles in ocular drug delivery. Jiang also studied 
usage of a hollow microneedle via intrascleral route of delivery. Jiang demonstrated tens 
of microliters of fluid could be injected into sclera. The major problem with this approach 
is that only a small amount of drug can be delivered using hollow microneedles [94, 95]. 
 
Figure 2.4.2.3. (A) Low and (B) high magnification image of hollow microneedle for 
SCS injection. Scale bar: 5 mm (A) and 500 µm (B). Copied from Patel et al [66]. 
 
This problem was solved by a novel approach of injecting fluid into the 
suprachoroidal space using a hollow microneedle.  The suprachoroidal space is a virtual 
space between the choroid and sclera that can expand to incorporate injected fluid. It is 
called a virtual space because the space does not exist but can be separated. The 
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attachment between the choroid and sclera is thought to be at the edge of two locations, 
which is the anterior and posterior portion of the eye.  This allows injected fluid to flow 
freely between the posterior portion of the eye. If the drug was injected into the side of 
the eye, the physiological feature of suprachoroidal space allows fluid to flow to the 
posterior portion of the eye [69].   
Patel et al. demonstrated the suprachoroidal space could be used to inject 50-100 
microliters of fluid [67]. Another major advantage of using a suprachoroidal injection is 
that it can be used to put drugs directly to the back of the eye. Patel et al. showed 
materials can be injected into the suprachoroidal space of rabbit, pig, and human eyes 
[67]. Patel also demonstrated that when various materials such as fluorescein and 
fluorescently tagged dextrans, bevacizumab, and polymeric particles were injected into 
rabbit eyes, their presence at the back of the eye was measured [66]. This technology was 
recently used to inject bevacizumab in a group of four patients and it was shown that the 
procedure was well tolerated with just a topical anesthesia [109]. Suprachoroidal space 
injection gives easy access to many unique locations inside the eye, such as ciliary body 
or macula, that are pharmacological targeting sites for many diseases such as age-related 
macular degeneration and glaucoma [23, 110, 111]. However, one of the problems for the 
suprachoroidal delivery is uncontrolled flow of fluid inside the suprachoroidal space 
allows only limited targeting ability. Therefore the injected fluid covers part of the eye 
but is not well targeted to ciliary body or back of the eye.  
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3 INTRASTROMAL DELIVERY OF BEVACIZUMAB USING 




Corneal neovascularization is invasion of vessels into the clear cornea. Corneal 
neovascularization can cause visual impairment due to blockage of visual field by 
ingrowth of vessels. It is estimated that corneal neovascularization develops in 1.4 
million patients per year and 12 % of these patients experience vision loss [112]. Corneal 
neovascularization could be caused by infectious pathogens, inflammatory responses, 
physical traumas, or degenerative diseases [113]. Conventional therapy for corneal 
neovascularization relies on steroids such as hydrocortisone, dexamethasone, prednisone, 
triamcinolone acetonide [113]. However, steroids carry concerns for serious side effects 
such as cataract and glaucoma and the increased in injection [114].  
Recently, anti-vascular endothelial growth factor (VEGF) treatments showed very 
promising results against treating corneal neovascularization [115]. Currently, topical and 
subconjunctival injection of bevacizumab is used in clinic to treat corneal 
neovascularization as an off-labeled use [116-118].  However, topical administration is 
extremely inefficient due to the effective barrier properties of corneal epithelium, and 
systemic delivery is often accompanied by side effects [6, 113, 119-121]. 
Subconjunctival administration is a better delivery method. However, there are still the 
possibility of causing side effects due to high dosage requirements and may not be 
suitable for long-term use. Possible side effects with prolonged use includes, causing 
thinning or erosive changes to the conjunctiva, sclera, and epithelium [113, 122, 123]. 
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Recently, intrastromal delivery of bevacizumab using a hypodermic needle have shown 
promising results [124]. Microneedle could make the intrastromal delivery simple and 
reliable procedure.  
Microneedles are individual needles or arrays of micrometer-sized needles that 
are manufactured by adapting the tools of the microelectronics industry [104, 125, 126]. 
Solid microneedles were originally used for drug delivery to the skin, either by creating 
micron-scale holes in the skin to increase permeability [92] or by coating drug onto 
microneedles for rapid or controlled release by dissolution within the skin [127, 128]. A 
number of different drugs and vaccines have been delivered to animals and human 
subjects in this way [129-132].  
More recently, microneedles have been studies for applications in the eye [69]. In 
a first study, solid microneedles coated with pilocarpine were applied to the cornea and 
shown to dramatically increase bioavailability of the drug in the anterior segment as 
evidenced by pupil dilation in rabbits [94]. Additional studies have addressed posterior 
segment delivery using solid and hollow microneedles for drug delivery into a scleral 
depot [95, 133] as well as drug delivery into the suprachoroidal space [66, 134]. 
In this study, we tested the hypothesis that microneedles coated with bevacizumab 
can deliver drug into the corneal stroma in a highly targeted and minimally invasive 
manner and thereby allow dramatic dose sparing compared to subconjunctival and topical 
delivery in an injury-induced neovascularization model. We designed the microneedles to 
be small enough to penetrate to a depth of hundreds of micrometers into the corneal 
stroma without crossing the corneal endothelium. This study assesses the efficacy of 
intrastromal delivery using microneedles in an injury-induced neovascularization model 
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and compares microneedle-based therapy to conventional topical and subconjunctival 
delivery of bevacizumab. We expect microneedle-based delivery to enable significant 
dose sparing by targeting bevacizumab precisely at the site of neovascularization in the 
corneal stroma to suppress blood vessel growth. This study presents the design, 
fabrication and characterization of microneedles coated with bevacizumab in both the ex 
vivo and in vivo rabbit eye to examine the efficacy and safety of this drug delivery 
method compared to topical and subconjunctival delivery.  
  
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Fluorescent Labeling of Bevacizumab 
Bevacizumab (Avastin, Genentech, South San Francisco, CA) was labeled using a 
SAIVI Alexa Fluor 750 Antibody/Protein labeling kit protocol (Invitrogen-Molecular 
Probes, Eugene, OR). Briefly, Alexa Fluor NHS esters were incubated with the protein in 
a basic medium (pH 9.3). Labeled protein (bevacizumab) was isolated and purified by gel 
filtration. The final dye-to-protein ratio (number of Alexa Fluor molecules coupled to 
each protein molecule) was determined to be between 2.5 and 3.5 according to a protocol 
from Invitrogen. Finally, this solution of labeled protein (8 mg/ml) was mixed with 
untagged bevacizumab (i.e, Avastin, 25 mg/ml) at a volumetric ratio of 1:1 and was 
stored in the dark at -4°C. 
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3.2.2. Enzyme-Linked Immunosorbent Assay (ELISA) of Bevacizumab 
A serial dilution of bevacizumab (6.25–50 ng⁄ml) was used to generate a standard 
curve. Bevacizumab-coated microneedles were dissolved in phosphate-buffered saline 
(PBS) and diluted as needed to bring the concentration in the ELISA assay range. Diluted 
solutions were put in triplicates into wells in a Maxisorp ELISA plate (Nunc, Roskilde, 
Denmark). Plates with vascular endothelial growth factor (VEGF165, R&D Systems, 
Minneapolis, MN) were coated overnight at 4°C in sodium carbonate buffer at pH 9.6. 
Plates were washed three times with PBS-T (PBS with 0.05% Tween-20) and blocked 
with 300 µl per well of 1% bovine serum albumin (BSA) in PBS for 2 h at room 
temperature. After three washes with 300 µl PBS-T each, 100 µl of bevacizumab-
containing samples were added in triplicate for 2 h at room temperature. They were then 
washed three times with PBS-T as above and 100 µl horseradish peroxidase-labeled goat-
anti-human IgG  (R&D Systems) in 0.1% BSA per well and then incubated for 2 h at 
room temperature. Washing was performed as described and 100 µL of TMB (3,3', 5,5"-
tetramethylbenzidine) substrate reagent solution (R&D Systems) was transferred into 
each well.  Reaction was terminated after 20 min by adding 50 µl of 0.5 M HCl to each 
well. Absorbance was measured spectrophotometrically at a wavelength of 450 nm 
(iMark Microplate Reader, Bio-Rad, Hercules, CA). 
 
3.2.3. Microneedle Fabrication And Coating 
To make coating formulations, above solution was further diluted with stock 
solution of bevacizumab (i.e., Avastin, 25 mg/mL) at a volumetric ratio of 1:1. The 
mixed solution was repeatedly centrifuged using Nanosep centrifuge filters (Port 
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Washington, NY) with a 3 kDa molecular weight cutoff until the retentate reached a 
concentration of 100 mg/mL of bevacizumab. This solution was then immediately mixed 
with 5% carboxymethylcellulose at a volumetric ratio of 1:3 to make the final coating 
formulation [135]  
Solid microneedles were fabricated by cutting needle structures from stainless 
steel sheets (SS304, 75 µm thick; McMaster Carr, Atlanta, GA) using an infrared laser 
(Resonetics Maestro, Nashua, NH) and then electropolished to yield microneedles of 
defined geometry that are 400 µm in length, 150 µm in width, 75 µm in thickness, and 
55° in tip angle, as described previously [127]. Prior to coating, microneedles were 
treated with plasma cleaner to enhance coating of the formulation on the needle. 
Microneedles were coated by dipping 10 to 40 times into an aqueous coating solution at 
room temperature.  
Hollow microneedles were fabricated from borosilicate micropipette tubes (Sutter 
Instrument, Novato, CA), as described previously [95]. A custom, pen-like device with a 
threaded cap was fabricated to position the microneedle and allow precise adjustment of 
its length, as described previously [67]. This device was attached to a gas-tight, 10-µl 
glass syringe (Thermo Scientific, Waltham, MA).  
 
 
3.2.4. Ex Vivo Injection procedure and microneedle coating. 
As a model drug, IgG antibody (20 mg/mL) was purchased from (Novus 
Biological, Littleton, CO) and mixed with carboxymethyl cellulose (2 wt%) at a 
volumetric ratio of 1:1 to make the final coating formulation [135]. Whole rabbit eyes were 
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purchased (Pel-Freez Biologicals, Rogers, AR) with the optic nerve attached. Eyes were 
shipped on ice and stored wet at 4°C for up to 2 days prior to use. Before use, eyes were 
allowed to come to room temperature, and any fat and conjunctiva were removed to 
expose the sclera. A catheter was inserted through the optic nerve into the vitreous and 
connected to a bottle of HBSS raised to a height that generated an internal eye pressure of 
10 mm Hg, which mimics the lowered intraocular pressure in the rabbit eye under general 
anesthesia. The microneedle was then inserted perpendicular to the corneal surface for 20, 
60, 120, and 180 s, and then removed. 
 
3.2.5. Induction of Corneal Neovascularization 
All animal studies adhered to the ARVO statement for the Use of Animals in 
Ophthalmic and Vision Research and were approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee (IACUC). To simulate corneal 
neovascularization associated with minor traumatic injury, male and female New Zealand 
rabbits (2.2–2.5 kg) were anesthetized with ketamine (17 mg/kg), xylazine (8.5 mg/kg) 
and acepromazine (0.5 mg/kg) subcutaneously. Following topical administration of 0.5% 
proparacaine hydrochloride to minimize discomfort, a single 7.0-gauge silk suture 
(Ethicon TG140, Blue Ash, OH) was placed at midstromal depth 1 mm away from the 
limbus of the rabbit cornea. This silk suture was left in the rabbit cornea for the duration 
of the experiment to induce neovascularization [136, 137]. For each animal, a suture was 




3.2.6. Measurement of Neovascularization 
During the experiment, the rabbit eye was imaged using a digital camera (Cannon 
Rebel T1i, Melvile, NY) with macroscopic lens (Cannon MP-E 65mm) at 3X 
magnification every two days after placement of the suture. The area of 
neovascularization was quantified by determining the area using Adobe Photoshop 
(Adobe, Jan Jose, CA).  
  
3.2.7. Experimental Treatment Groups 
Prior to all treatment procedures except for topical delivery, rabbits were 
anesthetized with ketamine (6 mg/kg), xylazine (4 mg/kg) and acepromazine (0.25 
mg/kg) subcutaneously. Reduced dose of anesthesia to reduce possible stress to an animal. 
A single drop of topical proparacaine ophthalmic solution was given as anesthesia.  The 
duration of each study was 18 days and, after the suture insertion, we waited 4 days for 
neovascularization to develop. All the treatments were done at day 4 except for the 

















Table 3.2.7-1. Treatment groups for injury induced corneal neovascularization study 
 
 
3.2.7.1 Untreated Group (UT) 
Other than applying sutures to the eye, these animals received no further 
treatments. 
 
3.2.7.2 Topical Delivery Group (TOP) 
Topical delivery of bevacizumab was given into the upper conjunctival sack 
without anesthesia three times per day (at approximately noon, 3:00 pm and 6:00 pm) on 
day 4 through day 18. Each drop contained 1250 µg of bevacizumab in 50 µl, for a daily 
dose of 3750 µg of bevacizumab and a total dose of 52500 µg of bevacizumab over the 
course of 14 days of treatment.  
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3.2.7.3 Subconjunctival Delivery Groups (SC) 
Bevacizumab was injected subconjunctivally with a 30-gauge hypodermic needle 
at the upper bulbar conjunctiva four days after suture placement. The high-dose group 
(SC-high) received 2500 µg of bevacuzumab (in 100 µL, i.e., Avastin). The low-dose 
group (SC-low) received 4.4 µg of bevacuzumab (Avastin was diluted with HBSS to 100 
µL). 
 
3.2.7.4 Microneedle Delivery Groups (MN) 
Microneedles each coated with 1.1 µg of bevacizumab were inserted at the site of 
a silk suture and left in place for 1 min to allow dissolution of the coating. For the one-
microneedle bolus delivery group (MN-1bolus), a single microneedle (i.e., 1.1 µg of 
bevacizumab) was given as a bolus dose four days after suture placement. For the four-
microneedle bolus delivery group (MN-4bolus), four microneedles (i.e., 4.4 µg of 
bevacizumab) were given as a bolus dose four days after suture placement. For the one 
microneedle – three doses delivery group (MN-1x3), a single microneedle (i.e., 1.1 µg of 
bevacizumab) was given as at 4, 6 and 8 days after suture placement (i.e., for a total dose 
of 3.3 µg of bevacizumab). For the microneedle placebo group (MN-placebo), four 
microneedles coated with formulation containing no bevacizumab was given as a bolus 
dose four days after suture placement. Finally, for the hollow microneedle bolus delivery 
group (MN-hollow), a hollow microneedle was used to inject 2 µl of 25 mg/mL 
bevacizumab (i.e., Avastin, dose of 50 µg bevacizumab) intrastromally at the site of a silk 
suture as a bolus dose four days after suture placement. Eyelid was left closed for 5 min 
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and all the tear fluid was wiped off to collect all the residual bevacizumab that was not 
able to penetrate into the stroma using small piece of a kimwipe. The used kimwipes and 
microneedles were collected and dissolved into HBSS to collected residual bevacizumab.  
 
3.2.7.5 Fluorescently Labeled Bevacizumab Imaging Study 
Prior to imaging procedure, rabbits were anesthetized by subcutaneous injection 
of ketamine/xylazine/acepromazine at a concentration of 6/4/0.25 mg/kg. Eyes were kept 
open using lid speculum for the whole duration of the imaging procedures. The 
fluorescent signal intensity in the rabbits was imaged on a Caliper Xenogen Lumina In 
Vivo Imaging System (IVIS) at 0, 2, and 4 days post insertion. Animals were imaged at 
745 nm excitation, 780 nm emission and 1 second exposure time. Fluorescence intensity 
was measured as background-subtracted average efficiency within a fixed region of interest 
(ROI) centered on the insertion site.  
3.2.7.6 Safety Study  
To identify possible microanatomical changes after intrastromal delivery using 
microneedles, we conducted a histological safety study using four study groups: (i) The 
untreated group received no suture and no other treatments. (ii) The suture-only group 
received a suture at day 0, but no other treatments. Animals were sacrificed on days 1, 10 
and 18 for histological analysis. (iii). The suture with non-coated microneedles group 
received a suture on day 0 and four non-coated microneedles inserted at the site of the 
suture on day 4. Animals were sacrificed on days 1, 6 and 14 for histological analysis. 
(iv) The suture with coated microneedles group received a suture on day 0 and four 
microneedles each coated with 1.1 µg of bevacizumab inserted at the site of the suture on 
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day 4. Animals were sacrificed on days 10 and 18 for histological analysis. Suture 
placement and microneedle application were carried out as described above. High 
magnification images were taken every day in all study groups to assess possible gross 
corneal damage. Corneal tissues were fixed in 10% formalin and embedded in paraffin. 
Hematoxylin-eosin (HE) or periodic acid-Schiff (PAS) staining was performed. 
 
3.2.7.7 Statistical Analysis 
Replicate pharmacodynamics experiments were done for each treatment group 
above, multiple (3 – 6) images from which the mean and standard error of means were 
calculated. Experimental data were analyzed using two-way analysis of variance 
(ANOVA) to examine the difference between treatments. In all cases, a value of p < 0.05 
was considered statistically significant. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Characterization of Microneedles Coated With Bevacizumab 
We first designed solid microneedles to penetrate into, but not across, the cornea 
and in that way deposit drug coated onto the microneedles within the corneal stroma at 
the site of microneedle penetration. These microneedles were made by laser-cutting the 
needle structures from stainless-steel sheets. Guided by the average rabbit corneal 
thickness of 400 µm [138] and possible tissue deformation during the needle insertion, 
the microneedles used for rabbit corneal insertion were 400 µm in length, 150 µm in 
width, 75 µm in thickness, and 55° in tip angle (Fig. 3.3.1.1.).  
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These microneedles were coated with a dry film of bevacizumab designed to 
rapidly dissolve off the microneedle after insertion into the cornea. Coatings were applied 




Figure 3.3.1.1. Image of microneedle used in this study. Scale bar indicates 2mm. 
 
3.3.2. Intrastromal Delivery of Bevacizumab Ex Vivo 
To determine whether microneedles were strong and sharp enough to penetrate 
and deliver coated bevacizumab into the cornea, Texas Red-labeled IgG was used as a 
model compound, coated onto microneedles and inserted into rabbit cadaveric cornea for 
20, 60, 120, and 180 s, and then removed. Bioavailability of IgG delivered using coated 
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microneedles was determined as a function of insertion time and coating amount (Fig. 
3.3.2.1.). Bioavailability increased with longer insertion time, probably because of 
incomplete coating dissolution at shorter insertion times. Bioavailability increased with 
smaller amounts of IgG coated probably because thinner coating films dissolved more 
quickly.  
We also sought to confirm that coated IgG molecules were delivered into the 
corneal stroma by taking brightfield, fluorescent, and H&E-stained images of the cornea 




Figure 3.3.2.1. Coated amount on the microneedles and amount delivered in ex vivo for 
Texas Red labeled IgG coated microneedles at for different insertion time of 20, 60, 120, 




3.3.3. Intrastromal Delivery of Bevacizumab In Vivo  
We wanted to quantify in vivo bioavailability of bevacizumab delivered from 
coated microneedles by tagging the bevacizumab with florescent dye. Although we 
characterized the delivery of IgG molecules using microneedles ex vivo, for the in vivo 
study we expect to have lower bioavailability due to washout by tear fluid. Alexa Fluor 
750 dyes were tagged to bevacizumab to quantify using ELISA. Two of the 10, 20, 30 or 
40 dips coated microneedles were inserted into the cornea of an anesthetized rabbit. 
Amount was quantified using ELISA. Labeled-bevacizumab-coated microneedles were 
inserted into but not across the cornea for 60 s and then removed. We decided to use 
insertion time of 60 s because drying of the corneal surface might cause pain in patients 
and we wanted to mimic possible clinical scenarios as much as possible for our 
experiments. 
Coating amount of bevacizumab on the microneedle increased linearly from 1.15 
µg to 7.6 µg (Fig. 3.3.3.1a). On the other hand, the delivery amount does not increase 
linearly with coating amount (Fig. 3.3.3.1a). As mentioned previously, large coating 
volume makes it difficult for the entire coating to penetrate and dissolve into mid layer of 
a cornea. Measured in vivo bioavailability is lower compared to ex vivo bioavailability, 
which was expected due to low hydration of the cornea in vivo compared to ex vivo and 
washout from the tear fluid that is only present in vivo. Endothelial cells cornea is 
constantly pumping water out from the cornea and this allows in vivo cornea to be less 
hydrated. The calculated delivery amounts of microneedles were similar to our previous 
in vivo study using fluorescein in rabbit [94]. Due to large loss of bioavailability for 30 
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and 40 dips-coated microneedles, we decided to use 20 dips-coated microneedles, which 
can deliver 1.14 ± 0.11 µg of bevacizumab, for all of our pharmacodynamics test. 
 
 
Figure 3.3.3.1. (a) Measured coating amount (µg), calculated amount delivered (µg), 
measured amount left on the needle (µg), and measured amount in tear fluid after the 
injection (µg).  
 
3.3.4. Efficacy Of Intrastromal Delivery of Bevacizumab Using Microneedles 
Compared To Topical Delivery 
To further assess the capability of microneedles as a drug delivery platform, we 
created injury-induced neovascularization in a rabbit model and delivered bevacizumab 
using both microneedles and topical eye drops. Topical eye drops of bevacizumab have 
been used before to treat corneal neovascularization, but with limited efficacy and 
adverse events for prolonged use [122, 123, 139]. We hypothesized that the highly 
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targeted delivery of bevacizumab within the corneal stroma provides a significant amount 
of dose sparing and better efficacy to suppress injury-induced neovascularization in a 
rabbit compared to topical delivery. A suture was inserted into the mid space of the 
cornea. After waiting for 4 days for the neovascularization to develop, all the treatments 
were started at day 4. All of the microneedles were coated one day prior to the animal 
experiments. To compare the pharmacodynamics between topical and microneedle 




Figure 3.3.4.1. Corneal neovascularization after suture-induced injury. Photographs of 
rabbit cornea in vivo 18 days after applying a suture (a) with no treatment (UT) and (b) 
with a single treatment of bevacizumab using solid microneedles (MN-4bolus). 
 
As negative controls, a group of rabbits were left untreated (UT) and another 
group of rabbits were treated with four placebo microneedles (MN-placebo). Untreated 
and placebo microneedles group showed similar kinetics with no statistical difference (p 
= 0.11) where the neovascularization area increased until day 10 and decreased slightly 
until day 18 (Figs. 3.3.4.1.a and 3.3.4.2.a). The peak neovascularization area for the 
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Figure 3.3.4.2. (a) Neovascularization area vs. time (days) and (b) comparison between 
vascularization area at day 10 and 18 for 4 treatment groups; untreated (UT), topical 
delivery (TOP), microneedle placebo (MN-placebo), and four-microneedles group (MN-
4bolus). * - indicates significant difference (two-way ANOVA) relative untreated group; 
v- indicates significant difference (two-way ANOVA) relative to topical eye drop group. 
 
For the topical delivery group (TOP), 3 topical eye drops were given every day 
from day 4 until the end of the experiment (day 18), which is a 52,500 µg of bevacizumab 
over period of 14 days or 3750 µg/day. Topical eye drops reduced neovascularization 
compared to the untreated eyes by 44% (day 10) and 6% (day 18) (Fig. 3.3.4.2.). The 
topical eye drops group showed an immediate inhibition of the blood vessel growth after 
starting the treatment at day 4. However, subsequently neovascularization area increased 
steadily until the end of the experiment. At day 18, topical eye drops group showed no 
significant difference between the untreated eyes (one-way ANOVA, p = 0.36). Two-way 
ANOVA analysis showed that change in vasculature area for topical group over time was 
significantly different from the untreated group (p < 0.0001).  
For the microneedles group (MN-4bolus), eyes were treated with 4.4 µg of 
bevacizumab using 4 microneedles. Microneedles reduced vasculature area compared to 
the untreated eyes by 65% (day 10) and 44% (day 18) (Figs. 3.3.4.1. b and 3.3.4.2. b). 
Two-way ANOVA analysis showed a significant difference between the microneedles 
group and untreated group (p < 0.0001). Total topical bevacizumab dose that was given 
during the whole experiment was 52,500 µg. Although microneedles group resulted 
significantly better response, the dose sparing that we were able to achieve using 
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microneedles was 11931 times compared to topical delivery. The fact that the delivery of 
just 4.4 µg of intrastromal delivery using microneedles outperformed the 52,500 µg of 
topical application shows the ineffectiveness of the topical delivery. Assuming that delivery 
by microneedles achieved 100% bioavailability, the ratio between the two delivery 
amounts gives us an estimated bioavailability of less than 0.01% for topical delivery. 
Topical administration is a very valuable route for delivering small molecules into the 
cornea because it is non-invasive and results in minimal adverse events compared with 
systemic administration. However, topical delivery is not an effective method to deliver 
high molecular weight protein therapeutics into cornea due to its low bioavailability.  
 
3.3.5. Efficacy Of Intrastromal Delivery of Bevacizumab Using Microneedles 
Compared To Subconjunctival Delivery 
Next we sought to compare the pharmacodynamics effect between 
subconjunctival and microneedles delivery methods. There are reports in the literature 
that showed inhibition of blood vessel growth via subconjunctival delivery of 
bevacizumab [140-143]. We hypothesized highly targeted delivery of bevacizumab within 
the corneal stroma provides significant amount of dose sparing to suppress injury-induced 
neovascularization in a rabbit compared to subconjunctival delivery.  
Compared to the untreated group (UT), we measured change in vascularization 
area in the eyes that were treated with high-dose (SC-high) and low-dose (SC-low) 
subconjunctival injection of bevacizumab. Based on the reported effective dose in 
literature [140-142], 2500 µg (i.e., 100 µL at 25 µg/µL) was given as a bolus on day 4 for 
the high-dose subconjunctival injection. For the low-dose subconjunctival injection, we 
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decided to match the microneedles dose that was able to inhibit neovascularization (Fig. 





Figure 3.3.5.1. (a) Neovascularization area vs. time (days) and (b) comparison between 
vascularization area at day 10 and 18 for 4 treatment groups; untreated, low dose 
subconjunctival, high dose subconjunctival, and 4 microneedles group. * - indicates 
statistical difference (two-way ANOVA) compared to the untreated group. 
 
Eyes treated with a low dose of 4.4 µg of bevacizumab using subconjunctival 
injection (SC-low) reduced neovascularization compared to the untreated eyes (UT) by 
5% (day 10) and –5% (day 18). However, two-way ANOVA analysis showed that change 
in vasculature area for the low-dose subconjunctival group over time was not significantly 
different from the untreated group (p = 0.05).  
For the high-dose subconjunctival injection (SC-high), eyes treated with 2500 µg 
of bevacizumab reduced neovascularization compared to the untreated eye by 62% (day 
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10) and 29% (day 18). A two-way ANOVA analysis showed that change in vasculature 
area for the high-dose subconjunctival group over time was significantly different from the 
untreated group (UT, p < 0.0001) and was not significantly different compared to the 
microneedles group (MN-4bolus, two-way ANOVA, p = 0.45).  
Although the pharmacodynamic responses for both microneedles group and high 
dose subconjunctival injection were similar, the dose sparing that we were able to achieve 
using microneedles was 568 times compared high-dose subconjunctival injection. The 
intrastromal delivery of just 4.4 µg gave a similar response to 2500 µg given by 
subconjunctival injection. Assuming that delivery by microneedles achieved 100% 
bioavailability, the ratio between the two delivery amounts gives us an estimated 
bioavailability of 0.18% for high-dose subconjunctival delivery.  
Subconjunctival injection is a valuable route for delivering therapeutics for 
corneal neovascularization. Subconjunctival injection delivers molecules into the site of 
neovascularization by using already generated vessels in the cornea, which acts as a 
conduit to deliver molecules to the site of action. This is because invasion of the blood 
vessel occurs from the subconjunctival space. However, subconjunctival delivery still 
requires a 568 times the dose of highly targeted intrastromal delivery. Considering 
possibility of high frequency of adverse events for prolonged topical administration of 
bevacizumab [113, 117, 122, 123], we expect intrastromal delivery could be an excellent 




3.3.6. Effect Of Bevacizumab Dose on Efficacy Of Intrastromal Delivery Using 
Microneedles 
In the experiments so far, a single bevacizumab dose of 4.4 µg was given by 
microneedles. We therefore investigated other doses to better optimize the dosing 
regimen. We first investigated a lower dose of 1.1 µg given as a bolus on day 4 using a 
single microneedle (MN-1bolus). This treatment reduced neovascularization compared to 
the untreated eye by 34% (day 10) and 10% (day 18), which was significantly better 
reduction in neovascularization compared to the untreated group (UT, two-way ANOVA, 
p = 0.001) and was significant worse reduction in neovascularization compared to higher-
dose microneedle group (MN-4bolus, two-way ANOVA, p < 0.0009). This shows that an 
intrastromal bolus of 1.1 µg bevacizumab is effective, but a bolus of 4.4 µg bevacizumab 
is more effective.  
We next investigated administration of bevacizumab as multiple sequential doses, 
in which eyes were treated with one microneedle administering 1.1 µg bevacizumab on 
days 4, 6 and 8 (i.e., for a total of 3.3 µg bevacizumab). This protocol reduced 
neovascularization area compared to the untreated eye by 50% (day 10) and 41% (day 
18), which was significantly better reduction in neovascularization compared to the 
untreated group (UT, two-way ANOVA, p < 0.0009) and was significantly different 
compared to the bolus high-dose microneedle group (MN-4bolus, two-way ANOVA, p = 
0.019). The three-dose protocol appeared to have a delayed effect on inhibiting 
neovascularization, where the first dose had only a partial effect, but after the third dose 
inhibition of neovascularization was equivalent to that achieve with the high dose bolus. 
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This shows that multiple small doses can be as effective as a single high-dose bolus, but 
administration of a single bolus dose should be simpler in possible future clinical practice.  
We finally investigated bolus intrastromal administration of an even higher dose 
of 50 µg of bevacizumab. This high dose would have required the use of 46-coated 
microneedles, which is impractical. We therefore used a Injection with a hollow 
microneedle (MN-hollow) reduced neovascularization compared to the untreated eye by 
74% (day 10) and 45% (day 18), which was significantly better reduction in 
neovascularization compared to the untreated group (UT, two-way ANOVA, p < 0.0009) 
and was not significantly different compared to the bolus high-dose microneedle group 
(MN-4bolus, two-way ANOVA, p =0.154). This shows that giving a bolus dose more 
than 4.4 µg of bevacizumab does not provide additional improvement. This may be 
because the 4.4 µg dose was able to inhibit further neovascularization and, based on the 
mechanism of bevacizumab action. Thus, the maximum effect of bevacizumab was 







Figure 3.3.6.1. (a) Neovascularization area vs. time (days) and (b) comparison between 
vascularization area at day 10 and 18for 4 treatment groups; untreated, 1 microneedle 
group, 1 microneedles for 3 times, 4 microneedles group, and hollow microneedles 
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group. * - indicates statistical difference (two-way ANOVA) compared to the untreated 
group. 
 
3.3.7. Safety Of Intrastromal Delivery Of Bevacizumab 
We analyzed the corneas of four study groups to assess the safety of microneedles 
insertion by both magnified inspection of the corneal surface in vivo and histological 
examination of tissue sections obtained at various times after microneedle treatment. Fig. 
3.3.7.2. a – 3.3.7.2. d shows a representative set of images of the corneal surface of a 
rabbit in vivo after insertion of a non-coated microneedle. Immediately after insertion and 
removal of the microneedle, a small puncture in the corneal epithelium is evident with a 
size on the order of ~100 µm (Fig. 3.3.7.1. a). By the next day, it was not possible to 
locate the insertion site even due to apparent repair of the epithelium (Fig. 3.3.7.1. b). 
Similarly, at later times the corneal surface continued to look fully intact and normal 
(Figs. 3.3.7.2. c – 3.3.7.2. d). We examined the injection site on a daily basis throughout 
the 18-day experiment, but we never saw any evidence of corneal opacity. We also 
examined eyes treated with bevacizumab-coated microneedles and again saw only a 
microscopic puncture in the corneal epithelium that disappeared within one day and was 
not associated with any complications (data not shown).   
In addition to examining the corneal surface, we sacrificed animals at different 
time points to look for changes in corneal microanatomical structure. Histological 
analysis was carried out by an investigator board certified in both ophthalmology and 
anatomic pathology. Comparison between untreated eyes and eyes treated by insertion of 
non-coated microneedles exhibited no significant changes in microanatomical structure 
of the cornea; no evidence of the corneal puncture could be found (Fig. 3.3.7.2. e – 
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3.3.7.2. f). There was also no presence of macrophages or significant vascularization 
observed. We also compared histological sections from eyes that only had a suture 
applied to eyes that had been suture and then treated four days later with 1.1 µg 
bevacizumab using a microneedle. In the sutured eyes, there were large numbers of 
inflammatory cells present (Fig. 3.3.7.2. g) but there were no significant differences seen 
between sutured eye with and without no bevacizumab treatment using microneedles (Fig. 
3.3.7.2. h).  
 
 
Figure 3.3.7.1. High magnification images of the cornea at the site of insertion of non-
coated microneedles. Arrow points to site of microneedle insertion. Scale bar indicates 1 
mm. 
 
Altogether, these data indicate that insertion of microneedles into the corneal is 
minimally invasive and thereby has few or no adverse effects on the eye. Overall, no 
adverse effects were seen in any experiments in this study. Although this analysis 
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suggests that microneedle insertion into the eye may be well tolerated, additional studies 
are needed to assess safety more fully. 
 
 
Figure 3.3.7.2. Histology images showing microanatomical structure of cornea for 4 
treatment groups; (a) untreated, (b-d) microneedle placebo, (e-f) suture only, (g-h) and 
suture and MN insertion. 
 
3.4. DISCUSSION 
In this study, we sought to study capability of coated microneedle to deliver 
protein therapeutics to treat corneal neovascularization and compare them to 
subconjunctival and topical delivery. A series of experiment were conducted to measure 
the vascularization area in rabbit model using various different delivery methods. In vivo 
studies showed that bevacizumab can be rapidly delivered into the rabbit cornea for 
sustained delivery for many hours from a depot formed in the cornea with approximately 
50% bioavailability. Injury induced corneal neovascularization model showed 52500 µg 
of topical delivery of bevacizumab decreased neovascularization area of 6% (day 18) 
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compared to untreated group. Topical delivery showed no statistical difference between 
untreated group at day 18. Whereas, 4.4 µg microneedle delivery was able to decrease in 
neovascularization area of 44% (day 18) compared to untreated group. This shows topical 
eye drops are very ineffective way to deliver protein therapeutics. We can expect that very 
small amount of drug will diffuse across the corneal epithelium, which has tight junctions 
around the epithelial cell that blocks penetration of the small molecules [6]. We expect 
damage caused by using large 7-gauge silk suture should enhance the topical penetration. 
However, the large hole created by the suture was not enough to create enough penetration 
to suppress neovascularization for 14 days.  
Subconjunctival injection of 2500 µg of bevacizumab reduced neovascularization 
compared to the untreated eye by 29% (day 18). High dose subconjunctival injection 
gave same response compared to the 4.4 µg bevacizumab coated microneedle delivery 
group. Two-way ANOVA showed no statistical difference between the microneedle and 
high dose subconjunctival delivery group with p-value of 0.484. Microneedle group were 
able to achieve same response compared to high dose of subconjunctival injection with 
568 times less dosage. Highly targeted delivery of an anti-VEGF therapeutic within the 
corneal stroma provides an effective means to suppress injury-induced neovascularization 
in the rabbit compared to subconjunctival and topical delivery. We expect dosage will be 
significantly lower in human because bevacizumab-binding kinetics is 7-8 times less in 
rabbits than human [144], thereby enabling long residence time of bevacizumab in the 
cornea.  
Safety study was done to examine the effect of intrastromal delivery using 
microneedles on corneal opacity and micro-anatomical structure. We expect that small 
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incision using microneedles do not change corneal opacity because of a minimal damage 
it causes. Much more invasive surgery such as laser-assisted in situ keratomileusis 
(LASIK) is preformed in about 1 million patients each year in United States [145] alone 
without causing corneal opacity. We also expect very minimal concern with possible 
infection due to the damages in corneal epithelium since corneal epithelium is one of the 
fastest healing tissues in our body [6]. During the duration of the safety and 
pharmacodynamics study more than 8000 high magnification images were taken around 
the insertion site and at all times, there was never an evidence in change in corneal 
transparency. Multiple highly magnified images were taken to examination of 
microneedle-treated eyes revealed no adverse effects.  
Recently there have been an increasing number of reports showing the efficacy of 
off label use of bevacizumab in treating corneal neovascularization [116-118]. However 
penetration of the high molecular weight (149kDa) drug into intact corneal epithelium is 
an issue. High dosage requirement for topical administration can results unwanted side 
effects with prolonged use includes, causing thinning or erosive changes to the 
conjunctiva, sclera, and epithelium [113, 122, 123]. Subconjunctival delivery gives better 
modality of delivery. However, there are still the possibility of causing side effects due to 
high dosage requirements and may not be suitable for long-term use. In clinics we expect 
microneedles treatment to be used as a supplementary treatment to immediately suppress 
the blood vessel ingrowth to cornea in addition to traditional topical or subconjunctival 
treatment. In clinics, we expect clinicians to make thoughtful decisions if patients can 
tolerate high dose of bevacizumab and its side effects. If not, we believe microneedles 
based delivery method is a great alternative treatment due to its significant amount of 
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dose sparing. The solid needles using for intrastromal delivery to administer a smaller 
payload (but given the tiny required dose of bevacizumab, it should be sufficient for this 
and other applications), but deposit the drug exactly at the site of microneedle insertion. 
This targeted deliver will enable us to achieve significant amount of dose sparing and 
formulation the system for longer-term bevacizumab delivery using the microneedles and 
microparticles.  
The microneedle delivery methods developed for bevacizumab delivery to treat 
corneal neovascularization set the stage for delivery of other agents into the corneal 
stroma, for example to treat corneal infections, or to deliver agents into other ocular 
target tissues, such as conjunctiva, sclera [146].  
 
3.5. CONCLUSION 
This study provides the first demonstration of intrastromal administration using 
coated microneedles to deliver of protein therapeutic. We compared the 
pharmacodynamics of bevacizumab in treating corneal neovascularization in injury 
induced animal model. We showed microneedle enable targeted administration into the 
midstromal space and that anti-VEGF drugs administered this way show four and two-
order-of-magnitude reduction in dose compared to topical and subconjunctival delivery, 
respectively. We showed microneedles does not affect corneal transparency and 
microanatomical structure. We concluded that highly targeted administration of 
bevacizumab into mid-stromal space allows significant dose sparing compared to both 
topical and subconjunctival delivery and may be applicable to minimally invasive 
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treatment of diseases of the anterior segments of the eye and may be applicable to 







4 FORMULATIONS TO TARGET DRUG DELIVERY WITHIN THE 




Current ophthalmic drug delivery is constrained by the many natural barriers of 
eye, which prevent a drug from effectively penetrating into targeting tissues [47]. Many 
ocular diseases can lead to blindness and are preventable if managed correctly. However, 
pharmacotherapies for many vision-threatening diseases are not delivered to the targeting 
part of the eye to best obtain treatment efficacy. Currently, free drug formulations are 
administered by topical or intravitreal injection. And sustained release formulations are 
delivered as an implant that are placed in vitreous. However, targeting sites for vision 
threatening disease such as glaucoma, uveitis, and age related macular degeneration are 
located in the uvea [147, 148]. In the case of many anti-glaucoma drugs, that site of 
therapeutic action is not on the corneal surface but at the ciliary body [110, 111]. And the 
targeting sites for many of the posterior diseases are not at the center but along the 
periphery of the eye in the layer of choroid [147, 148]. Furthermore the non-targeted 
nature of currently used delivery methods allows possible adverse events and toxicity in 
the surrounding tissues. For example, the poorly targeted nature of eye drops leads to 
extensive systemic exposure, which causes up to 8-53% of glaucoma patients taking 
topical anti-glaucoma drugs to experience side effects [149, 150]. In case of intravitreal 
administration of steroids, unwanted contact with lens promotes the formation of cataract 
in 6.6% of the patients [151]. In addition, delivering sustained release formulation often 
requires surgical procedures to insert the implants. A novel delivery method that can 
deliver controlled release formulation around the eye in a non-invasive manner to 
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maintain high therapeutic levels of a drug in a targeting region of the eye, should provide 
more effective therapy for many of the vision threatening eye diseases. 
Suprachoroidal injection allows an access from space immiditately above ciliary 
body anteriorly to immediately above the choroid posteriorly. The SCS is a potential 
space located between sclera and choroid that can expand to accommodate a fluid or drug 
formulation. The location of the SCS adjacent to the target site for treatment of diseases 
like glaucoma, wet AMD, diabetic retinopathy, and uveitis may provide higher drug 
levels in the target tissues. For this reason, the SCS represents a promising new site of 
administration for treatment many ocular diseases and has become a recent focus of drug 
delivery research [62-64, 152].  
Recently, researchers have shown that there are several ways to access the 
suprachoroidal space. However, these methods involve using invasive techniques such as 
catheters or implants that are surgically placed into the eye to access suprachoroidal 
space [62, 65, 153]. Microneedle’s microscopic size makes it an ideal device to deliver 
materials into suprachoroidal space. Microneedle allows precise placement of the needle 
tip right at the suprachoroidal space. Previously, microneedles have shown to deliver 
nanoparticles and microparticles into rabbit, pig, and human cadaver eyes [67]. In vivo 
study in rabbit model showed microneedle can deliver particles as large as 10 µm to 
posterior segment [66]. 
Suprachoroidal space injection provides precise placement of the drugs to the site 
of action. However, we want to better target within the suprachoroidal space. Using 
aqueous formulation, the injected polymeric particles covers a portion of the 
suprachorodial space but not well targeted towards either anteriorly to ciliary body or 
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posteriorly to the whole layer of the choroid. Anteriorly, injected formulation quickly 
spreads away from the injection site to target ciliary body [66-69].  
To improve on this technique, we have developed formulation to enhance the 
spreading of the particles or to immobilize the particles at the site of injection. In this 
study, we tested the hypothesis that particles injected into the suprachoroidal space can be 
localized at the site of injection or broadly distributed throughout the suprachoroidal 
space by controlling properties of polymeric formulation such as molecular weight, and 
rheology. We used properties of non-Newtonian fluids to modulate the movement of both 
polymers and embedded particles. Many polymers we tested exhibit Non-Newtonian or 
shear-thinning behavior because of its molecular properties and structure. Non-
Newtonian fluids are characterized by increase in viscosity as shear rate decreases or 
decrease in viscosity as shear rate increases. To widely distribute particles, we used 
weakly non-Newtonian or shear thinning polymers to prevent polymers and embedded 
particles to increase its viscosity upon injection into the tissue (e.g. low shear 
environment). To localize the delivery, we used strongly non-Newtonian (or shear 
thinning) polymers to significantly increase polymers viscosity upon injection into the 
tissue (e.g. low shear environment). 
We first determined the mobility of particles inside the suprachoroidal space as a 
function of particle size in a saline formulation. We then examined the extent to which 
polymeric formulation could affect mobility of particles inside the suprachoroidal space 
to deliver particles immediately above the ciliary body and around the ocular globe in the 
suprachoroidal space, which exist immediately above the choroid. For the first time, this 
study presents methods to deliver polymeric particles to ciliary body and choroid as a 
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function of properties of polymeric formulation, such as rheology, and molecular weight. 
Overall, this study shows that the suprachoroidal route of administration can provide 
targeted delivery of particles to ciliary body and entire surface of choroid in minimally 
invasive way using a microneedle.  
 
4.2. MATERIALS AND METHODS 
   
4.2.1. Microneedle Fabrication 
Microneedles were fabricated from 33-gauge needle cannulas (TSK Laboratories, 
Tochigi, Japan). The cannulas were shortened to approximately 750 µm in length and the 
bevel at the orifice was shaped using a laser (Resonetics Maestro, Nashua, NH). The 
microneedles were electropolished using an E399 electropolisher (ESMA, South Holland, 
IL) and cleaned with deionized water, as described previously [66]. Microneedles were 
attached to gas-tight, 100-250 ml glass syringes (Thermo Scientific™ Gas-Tight GC 
Syringes, Waltham, MA) containing the formulation to be injected. 
 
4.2.2. Formulations  
All solutions for injection were prepared by mixing 2 wt% carboxylate-modified 
FluoSpheres in water (Invitrogen, Grand Island, NY), 0.2 wt% Sky Blue particles in 
water (Spherotech, Lake Forest, IL) and polymer formulations dissolved in Hank’s 
balanced salt solution (HBSS, Manassas, VA) at a volumetric ratio of 1:1:2. Fluospheres 
were labeled with red-fluorescent dye and Sky Blue particles were labeled with infrared-
fluorescent dye. Particles having diameters of 20 nm, 200 nm, 2 µm or 10 µm were used, 
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but in a given formulation, only one diameter particle was used and both the FluoSpheres 
and Sky Blue particles had the same diameter. The polymeric formulations were made 
using carboxymethyl cellulose (Sigma Aldrich, St. Louis, MO), hyaluronic acid (R&D 
Systems, Minneapolis, MN), methyl cellulose (Alfa Aesar, Ward Hill, MA), and 
DiscoVisc® (Alcon, Fort Worth, TX).  
 
4.2.3. Viscosity Measurements 
The viscosity (η) measurements were carried out on an MCR300 controlled stress 
rheometer (Anton Paar, Ashland, VA) equipped with Peltier elements for temperature 
control and an evaporation blocker that enables measurements of polymer solutions at 
elevated temperature in a cone-plate geometry. The viscosities of all samples were 
measured at shear rates from 0.01 s-1 to 100 s-1. The viscosity reported for each sample in 
this study was matched at a shear rate of 0.1 s-1. The measurements were carried out at 
39°C to mimic the temperature of the living rabbit eye [154]. Multiple measurements 
were performed, and their average is reported. 
 
4.2.4. Ex Vivo Injection Procedure 
Whole rabbit eyes were purchased (Pel-Freez Biologicals, Rogers, AR) with the 
optic nerve attached. Eyes were shipped on ice and stored wet at 4°C for up to 2 days 
prior to use. Before use, eyes were allowed to come to room temperature, and any fat and 
conjunctiva were removed to expose the sclera. A catheter was inserted through the optic 
nerve into the vitreous and connected to a bottle of BSS raised to a height that generated 
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an internal eye pressure of 10 mm Hg, which mimics the lowered intraocular pressure in 
the rabbit eye under general anesthesia. The microneedle was then inserted perpendicular 
to the sclera surface 3 mm posterior from the limbus. A volume of 50 µL or 100 µL was 
injected within 15 s and an additional 30 s was allowed before removing the microneedle 
from the eye to prevent excessive reflux. 
 
4.2.5. In Vivo Injection Procedure 
Microneedle injections were carried out in New Zealand White rabbits (Charles 
River Breeding Laboratories, Wilmington, MA). All injections were done under systemic 
anesthesia by subcutaneous injection of a mixture of ketamine/xylazine/acepromazine at 
a concentration of 17.5/8.5/0.5 mg/kg. A drop of 0.5% proparacaine was given 2 - 3 min 
before injection as a topical anesthetic. To perform a suprachoroidal injection, the eyelid 
of the rabbit eye was pushed back and the microneedle was inserted into the sclera 3 mm 
posterior to the limbus in the superior temporal quadrant of the eye. A volume of 50 µL 
or 100 µL was injected within 15 s and additional 30 s was allowed before removing the 
microneedle from the eye to prevent excessive reflux. At terminal study endpoints, 
rabbits were euthanized with an injection of pentobarbital through the ear vein. The eyes 
were enucleated after death and processed for further analysis. All animal studies were 
carried out with approval for the Georgia Institute of Technology Institutional Animal 
Care and Use Committee (IACUC).  
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4.2.6. In Vivo Imaging Procedure 
Rabbits were anesthetized by subcutaneous injection of a mixture of 
ketamine/xylazine/acepromazine at a concentration of 6/4/0.25 mg/kg, and 
suprachoroidal injection was performed as described above. Eyes were then kept open 
using a lid speculum for the duration of the imaging procedures. The fluorescent signal 
intensity in the rabbits was measured on a Caliper Xenogen Lumina In Vivo Imaging 
System (IVIS Lumina, Waltham, MA). Animals were imaged at 680 nm excitation, 720 
nm emission and 1 s exposure time. Fluorescence intensity was measured as background-
subtracted average efficiency within a fixed region of interest (ROI) centered on the 
microneedle injection site.  
 
4.2.7. Tissue Processing And Measurement Of Fluorescence Intensity 
Immediately after suprachoroidal injection in rabbit eyes ex vivo and immediately 
after enucleation of rabbit eyes in vivo, eyes were snap frozen in an isopropyl alcohol (2-
isopropanol, Sigma Aldrich, St. Louis, MO) bath, which was cooled in dry ice. After the 
eyes are completely frozen, they were removed and eight radial cuts were made from the 
optic nerve on the posterior side to the limbus on the anterior side of each eye. Each of 
the eight pieces of cut tissue was then peeled away outward exposing the chorioretinal 
surface inside the eye. This made the eyes into a flat mount-like configuration, exposing 
the injected dyes for imaging. Brightfield and fluorescence images (Fig. 4.3.1.1) were 
taken using digital camera (Cannon Rebel T1i, Melvile, NY). Green light bulb (Feit 
Electric, Pico Rivera, CA) was used to excite the florescent particles and red camera filter 
(Tiffen red filter, Hauppauge, NY) was mounted on a digital camera to visualize the 
 72 
distribution of particles inside the suprachoroidal space. Obtained images were used to 
quantify the suprachoroidal space area containing injected particles using Adobe 
Photoshop (Adobe, Jan Jose, CA). Each of the eight tissue pieces was then divided into 
additional two pieces. The cuts were made 6 mm antero-posteriorly from the ciliary body, 
which is the starting point of the suprachoroidal space. From hereafter, we will be 
refereeing to ocular tissue 0 mm from the ciliary body to 6 mm away from the ciliary 
body as “anterior SCS”. Likewise, ocular tissue 6 mm away from the ciliary body to the 
rest of the ocular tissue will be hereafter referred to as “posterior SCS”. This results in a 
total of 16 tissue pieces from each eye. Each of the 16 pieces was then put into separate 
vials containing BSS solution and homogenized (Fisher Scientific PowerGen, Pittsburgh, 
PA) to extract injected fluorescent particles. The liquid part of the homogenate was 
pipetted out into 96 well plates to measure fluorescent signal intensity (Synergy 
Microplate Reader, Winooski, VT). In order to quantify radial distribution of particles, 
ocular tissue was divided into 2 segments radially: ocular tissue in -90° to 90° from the 
injection sites (hereafter referred to as “superior SCS”) and ocular tissue in 90° to 270° 
from the injection site (hereafter referred to as “inferior SCS”). 
 
4.2.8. Statistical Analysis 
Replicate experiments were done for each treatment group, from which the mean 
and standard deviation were calculated. Experimental data were analyzed using both one 
and two-way analysis of variance (ANOVA) to examine differences between treatments. 
In all cases, a value of p < 0.05 was considered statistically significant. 
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4.3. RESULTS AND DISCUSSION 
4.3.1.1 Distribution of Nanoparticles and Microparticles in the Suprachoroidal Space 
Fluorescently tagged, polystyrene particles with various diameters (20 nm, 200 
nm, 2 µm, 10 µm) were suspended in 50 µL of Hank’s balanced salt solution (HBSS) and 
injected into the SCS of New Zealand White rabbit eyes using a hollow microneedle 
inserted 3 mm posterior to the limbus. The distribution and number of particles in the 
SCS was determined immediately after injection into rabbit cadaver eyes ex vivo and was 
determined 14 or 112 days after injection into living rabbit eyes in vivo. Fig. 4.2.8.1. 
displays images of a representative eye cut open in a flat-mount presentation showing the 
distribution of fluorescent particles in the SCS. Quantitative analysis of images like these 
was used to generate the SCS surface area coverage data described immediately below.    
  
	  
Figure 4.2.8.1. Bright field image of flat mounted eye (a), florescent image of the red 
fluorescent particles (b), and fluorescent image of near-infrared particles (c). 
 
Immediately after injection, the particles covered 29% - 42% of the SCS surface 
area (Fig. 4.2.8.2). There was no significant effect of particle size on SCS surface area 
coverage (one-way ANOVA, p > 0.10). Fourteen days after injection, the SCS coverage 
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area did not significantly change for any of the particle sizes studied. Two-way ANOVA 
analysis showed no significant difference between the SCS coverage area (p = 0.75) and 
particle size (p = 0.11). Likewise, there was no interaction between time and size of the 
particles (p = 0.16). One-way ANOVA was also done, but no significant difference was 
shown for the individual particle sizes between days 0 and 14.  
Between days 14 and 112, there was a significant decrease in the SCS coverage 
area to 24% - 32% of the SCS. This represents a reduction of 9% - 35% of SCS coverage 
area. Two-way ANOVA analysis showed a significant difference in SCS coverage area 
between day 14 and 112 (p < 0.001), but there was no significant effect of particle sizes 
(p = 0.167).  There was no significant interaction between time and particle size (p = 
0.21). One-way ANOVA was also done and a significant change in SCS coverage area 
was shown for 20 nm, 2 µm, and 10 µm particles (but not 200 nm particles) between days 
14 and 112.  
In addition to measuring SCS coverage area, fluorescent signal intensity of the 
particles was measured. The fluorescent signal intensity of particles in the SCS between 
days 0 and 14 showed no significant difference (two-way ANOVA) as a function of time 
(p = 0.13) and particle size (p = 0.05). There was also no significant interaction between 
time and particle size (p = 0.1). This suggests that there was no significant clearance of 
particles during the first 14 days after injection.  
However, the number of particles appeared to decrease between days 14 and 112, 
as shown by fluorescence intensities of 31% - 61% of original values (at day 0). This 
suggests a 39% - 69% reduction in the number of particles. Two-way ANOVA analysis 
showed a significant difference in particle fluorescence between days 14 and 112 
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(p<0.001), but not as a function of particle size (p = 0.17). There was also no significant 
interaction between time and particle size (p=0.21). One-way ANOVA analysis 
demonstrated a significant decrease of fluorescence intensity for the smaller particle sizes 
(20 nm, 200 nm and 2 µm), but not for the 10 µm particles.  
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Figure 4.2.8.2. Suprachoroidal space injection of nanoparticles and microparticles. (a) 
Suprachoroidal surface coverage area as function of time and particle sizes. (b) Mass of 
particles in suprachoroidal space as a function of time and particle sizes. * - Statistical 
difference (one-way ANOVA) between day 14 and 112. v- Statistical difference (two-
way ANOVA) between day 14 and 112. 
 
Overall, these data show that the injected particles spread over a coverage area of 
about one-third of the SCS. Within 14 days, there was little movement or loss of particles 
in the SCS, but after 112 days, there was a significant reduction in coverage area to about 
one-quarter of the SCS and there was a significant reduction in the number of particles in 
the SCS to about half of the particles originally injected.  
We expect that loss of fluorescent particles is either due to removal by 
macrophages (i.e., true clearance) or a reduction of the fluorescence signal intensity over 
time (i.e., artifact). To assess the relative roles of these two possible mechanisms, we 
measured the decrease in fluorescence intensity of 20 nm, 200 nm, 20 µm, and 10 µm 
particles in HBSS after storage for 112 days in the dark at 39 °C to mimic conditions in 
the SCS of the rabbit eye. These particles lost 25±6.5% of their fluorescence signal 
intensity. This suggests that particle clearance from the eye may not be as extensive as 




4.3.2. Polymer characterization 
The main objectives for this study were to develop formulation to deliver 
polymeric particles immediately above the choroid and ciliary body.  
In order to target choroid layer, injected particle need to travel around the ocular 
globe to cover entire layer of the SCS, which is immediately above choroid.  For 
targeting ciliary body, injected particles should be immobilized at the site of the injection 
and immediately above the ciliary body. To achieve this goal, various polymeric 
excipient formulations were injected along with particles to decrease or increase the 
mobility of particles. The hypothesized is that high molecular weight, and weakly non-
Newtonian materials rapidly expand its volume along with embedded particles and 
causes movement of particles inside the suprachoroidal space. Likewise, we hypothesized 
that strongly non-Newtonian material resists spreading of embedded particles away from 




Figure 4.3.2.1. Molecular structure of (a) carboxymethyl cellulose (CMC), (b) 
hyaluronic acid (HA), (c) methyl cellulose (MC), and (d) poly vinyl alcohol (PVA). 
 
Delivery of polymeric particles were critical parameter that we have considered 
because of its capability to encapsulate variety of compounds and achieve long-term 
sustained release that can last many months [155]. We also wanted to use materials that 
are currently used in pharmaceutical formulation to avoid additional toxicology studies to 
be readily applicable in human use. We also wanted a system that is simple and easy to 
use. Many in situ gelling polymers such as solvent removal, temperature, pH, or light 
mediated did not have characteristics that we were looking for. Solvent removal system 
involves using organic solvents that denature polymeric particles or proteins. pH or 
temperature sensitive polymers have very low viscosity before the injection that will 
quickly spreads away from the injection site before it gels. Furthermore, light sensitive 
polymers require complex equipment and procedures to be more broadly applicable. We 
needed a formulation that could resist initial spreading of polymeric particles after the 
injection and could deliver polymeric particles for a long-term sustained release. For 
immobilizing particles, we need a formulation that gels to hold the particles in place. But 
we also need a formulation that has significant viscosity initially to localize the injected 
formulation during the injection procedure. 
In order to promote spreading of particles, we decided to use a polysaccharide as 
a potential material due to its excellent biocompatibility [156]. Ideal material to should 
have very hydrophilic characteristic to absorb water to promote spreading of embedded 
particles. The material should also have high molecular weight to maintain its 
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concentration within the suprachoroidal space and keep the suprachoroidal space open 
during swelling process, which will promote movement of embedded particles as 
polymer swell inside the suprachoroidal space. Furthermore, the ideal material should not 
exhibit increase in viscosity at low shear rate because we do not want the material to gel. 
We decided to use hyaluronic acids based material due to its excellent biocompatibility 
and its favorable characteristics. Rheological analysis showed HA based materials does 
not increase as its viscosity at low shear rate. Viscosity rapidly plateaus out at shear rate 
of less than 1 s-1. However, at higher shear rate, the HA exhibits non-Newtonian property 
to make injection easier.  
In addition to HA formulation, we decided to use one additional HA based 
formulation that are commercially available in the market. Discovisc® (DV) is a 
viscoelastic material that is used in ophthalmic surgery to protect delicate ocular tissue 
[157]. DV has contains 17% (w/v) of 1.7 MDa HA formulation in addition to low 
molecular weight (22 kDa) sodium chondroitin sulfate [157]. We wanted to assess 
material that is already approved by food and drug administration (FDA). Smaller 
particles are more likely to be cleared by macrophages, which was also evident in 
previous aqueous formulation study. Therefore all the experiment was done using 10 µm 
particles. 
In order to study increase the suprachoroidal coverage area we tested the effect of 
concentration of polymeric excipients on particle’s suprachoroidal space coverage area. 
Considering majority of compound in DV is HA we expected it to have similar 
rheological characteristics compared to pure HA formulation. Rheological analysis of DV 
indeed showed similar characteristics to pure HA formulation (Fig. 4.3.2.2.). In addition 
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to DV formulation, we tested 2 and 4 times the concentration of DV to study the effect of 
concentration. The hypothesis is that increase in concentration enhances the spreading 
due to increase swelling of the volume within suprachoroidal space. 
 
 
Figure 4.3.2.2. Rheological behavior of hyaluronic acid and Discovisc® showing the 
viscosity as a function of shear rate (s-1). 
 
We again decided examine polysaccharides as potential formulation to 
immobilize particles inside the suprachoroidal space due to its excellent biocompatibility 
[156]. We selected 700kDa carboxymethylcellulose (CMC) and 90kDa methylcellulose 
(MC) as a potential material to immobilize polymeric particles due to many of its 
favorable characteristics. Both 700kDa CMC and 90kDa MC are shear thinning material 
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that has low viscosity at high shear stress but it restores its high viscosity at low shear 
rate (Fig. 4.3.2.3.). Rheological analysis showed these materials have extremely strong 
non-Newtonian (Fig. 4.3.2.3.). Upon injection, the materials restores its high viscosity to 
immobilize the injected particles in SCS. Shear thinning property of the CMC comes 
from the high molecular weight nature of the material. Rheological analysis of lower 
molecular weight (90 and 250 kDa) CMC shows this property (Fig. 4.3.2.3.b). In addition, 
this shear thinning property will lower required pressure to achieve successful injection 
of a high viscosity material during the injection procedure. In order to experimentally test 
the hypothesis and its impact on spreading of the embedded particles inside the 
suprachoroidal space, we also tested 90kDa CMC (12%) that shows relatively weakly 





Figure 4.3.2.3. Rheological behavior of CMC, MC, and HA showing the viscosity as a 
function of shear rate (s-1). (b) Rheological behavior of different molecular weight of 
CMC (log-log plot). 
 
4.3.3. Formulations to enhance spreading of particles inside the suprachoroidal 
space 
To test spreading of particles inside the suprachroroidal space, we sought to 
compare suprachoroidal space coverage area immediately after the injection and 14 days 
after injection. All the initial suprachoroidal space coverage area was done in ex vivo 
eyes (Pel-Freez Biologicals), as it would not make difference to do the experiment in live 
rabbit. SCS coverage area of HBSS formulation was also done as a comparison. 
Immediately after the injection, the particles with polymeric formulations covered 8.3% - 
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11% of the SCS surface area (Fig. 4.3.3.1.a). This is expected because the formulation is 
viscous. In contrast HBSS formulation covers 42% of the SCS space initially.  
Fourteen days after injection, the SCS coverage area drastically changed for all 
the HA based formulations. SCS surface coverage areas for 950 kDa HA, 1X, 2X, 4X-
DV formulation covered 61% - 85% of the SCS surface (Fig. 4.3.3.1.a). This represents a 
5.7- to 8.7-fold increase in SCS coverage area for HA based formulation between days 0 
and 14. These significant changes in SCS coverage area showed HA based formulations 
are capable of enhancing spreading of embedded particles. In comparison to HBSS 
formulation, the polymeric formulations showed 0.77 – 1.3 fold increase in 
suprachoroidal space coverage areas after 14 days. One-way ANOVA analysis of between 
HBSS and polymeric formulations (950kDa HA, 1X, 2X, 4X-DV) showed p-values of 
0.018, 0.00052, 0.0094, and 0.0019, respectively. Statistically significant difference was 
shown for all the HA based formulations. The results also showed the higher 
concentration of HA formulation resulted in increase in SCS coverage area of the 
delivered particles. Although there was an increase in coverage area between 1X and 2X-
DV formulation, we did not observe any statistically significant increase in coverage area 
between 2X and 4X-DV formulations. The mechanism behind this needs further studying. 
In an effort to examine if polymeric formulation could be used to cover entire SCS, we 
tested increased volume (100µ) of 4X-DV formulation. The results showed the coverage 
of the entire SCS coverage with single injection after 14 days. In addition to measuring 
the SCS coverage area 14 days after the injection, we also used IVIS (in vivo imaging 
system) to get a sense of time scale that this movement of particles is happening. The 
florescent measurement at the injection site over period of 14 days showed all the 
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movement of particles happened within 2 days after injection (Fig 4.3.3.1.c). However, 
further studies are required to fully characterize the movement of particles at different 





Figure 4.3.3.1. (a) Suprachoroidal surface coverage area for different HA based 
polymeric compounds between 0 and 14 days. (b) Eyes injected with 4X concentration of 
DiscoVisc® formulation after 14 days. Merged bright field florescent image showing the 
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spreading of particles inside the suprachoroidal space. (c) Change in signal intensity at the 
site of injection over the period of 14 days after the injection for different polymeric 
formulations. 
Physical delivery of particles to the targeting site is important but how much we 
can deliver is also an important factor to consider. In addition to SCS coverage area, 
particle weight percent distribution was measured antero-posteriorly to characterize the 
mobility of particles inside the suprachoroidal space. For the in vivo experiment, the 
amounts of particles (%) in posterior SCS for 950kDa HA, DV  (50 µL), 2X DV (50 µL), 
4X DV (50 µL), and 4X DV (100 µL) formulation were 31-49 %. Likewise, amount of 
particles (%) for HBSS formulation was 29±15%. One-way ANOVA analysis of HBSS 
and HA formulations showed p-value of 0.69, 0.021, 0.0070, 0.012, and 0.00014, 






Figure 4.3.3.2. Distribution of particles inside the suprachoroidal space in different 
locations within the ocular globe. (a) Distribution of particles (wt%) in anterior and 
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posterior SCS (b) Distribution of particles (wt%) in superior and inferior SCS from the 
injection site.  
Amount of particles (%) radially in superior and inferior SCS was also measured 
(Fig. 4.3.3.2.b). Amount of particles in the inferior SCS were 22 - 30% of injected 
particles. Likewise, HBSS formulation showed 11% of the injected particles in superior 
SCS. One-way ANOVA analysis of HBSS and polymeric formulation showed p-value of 
0.05, 0.13, 0.0082, 0.020, and 0.0068 respectively. Statistically significant differences 
were found for 2X DV (50 µL), 4X DV (50 µL), and 4X DV (100 µL). Particle weight 
percent analysis showed statistically significant amount in opposite to the injection site 
and posteriorly compared to HBSS formulation. The HA based formulation failed to 
achieve an even distribution of particles radially throughout the whole ocular globe. 
However, we were able to deliver significant amount of particles from the injection site 
to 180 degrees away from the injection site.  
 
4.3.4. Formulations to immobilize particles inside the suprachoroidal space 
To test the hypothesis that strongly non-Newtonian material resists spreading of 
embedded particles away from the injection site. The main parameter that we measured 
was the suprachoroidal space coverage area. Viscosity of all the polymers was set at 
approximately 55 Pa-s at a shear rate of 0.1 s-1. This was viscosity of 90 kDa of 
carboxymethyl cellulose (12%) at 39 °C. This was chosen because it was high enough 
viscosity for 90 kDa of carboxymethyl cellulose to inject through microneedles and be 
able to get accurate volume of injection. All of the initial suprachoroidal space coverage 
was measured using ex vivo eyes (Pel-Freez Biologicals). Smaller particles are more 
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likely to get cleared by macrophages, which was also evident in previous aqueous 
formulation study. Therefore all the experiment was done using 10 µm particles. 
Immediately after injection, polymeric formulations (700 kDa CMC, 90 kDa 
CMC, 90 kDa MC) covered SCS surface area of 7 – 10 %. Likewise HBSS formulation 
showed SCS coverage area of 42%. Initial suprachoroidal space coverage area of all the 
polymeric formulation, which had viscosity of 55 Pa-s, was 80% smaller than the HBSS 
formulation.  
Fourteen days after injection, SCS surface coverage area of 700kDa CMC and 
90kDa MC did not significantly change except 90kDa CMC formulation. Between days 0 
and 14, SCS surface coverage area of polymeric formulations (700kDa CMC, 90kDa 
CMC, 90kDa MC) increased 0.17 – 4.17 folds. One-way ANOVA showed significant 
difference in SCS coverage area for 90kDa CMC (p=0.0007) but no statistical difference 
was found for 700kDa CMC and 90kDa MC (p = 0.16 and 0.33, respectively). This was 
expected because of 90kDa CMC showed lower viscosity increase compared (Fig. 
4.3.2.3a) to 700kDa CMC and 90kDa MC formulations.  
Forty days after injection, SCS surface coverage area of 700kDa and 90kDa CMC 
was 12 and 36%. SCS surface coverage area of 90kDa CMC between 14 and 40 days did 
not show significant difference (p= 0.08 and 0.9, respectively). Sixty days after injection, 
SCS surface coverage area of 700kDa increased 0.20 folds. 700kDa CMC between 0 and 
60 days showed progressive increase up to 2 folds with statistically significant difference 
(p=0.001).  
Overall, this data showed that strongly non-Newtonian material at lower shear 
rate is capable of slowing down the spreading of particles inside the SCS up to 2 months. 
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We expect higher concentration of 700kDa CMC will be capable of slowing down the 
spreading of particles longer periods of time due to higher viscosity at lower shear rate 
(Fig. 4.3.4.1.). Extremely strongly non-Newtonian property of 700kDa CMC allows 
reliable injection through microneedles. This is because fluid flowing through the 
microneedle will experience very high shear stress, which will lower the viscosity of 
material flowing through the needle. We tested up to 3 wt% of 700kDa CMC solution 
and able to reliably inject through the microneedles (Data not shown). However, we 





Figure 4.3.4.1.  (a) Suprachoroidal space coverage area as a function of polymeric 
excipient formulation and time. (b) Rheological behavior of different weight percent of 




Suprachoroidal space (SCS) injection provides access to many unique locations 
within the ocular globes such as ciliary body and choroid. Microneedle’s micron sized tip 
simplifies the delivery into the suprachoroidal space by designing the tip to just penetrate 
into but not across the suprachoroidal space. Previous research in this area showed 
microneedles could be used to inject particles as large as 10 µm into the suprachoroidal 
space [66]. This study builds on the previous success of using microneedles to deliver 
materials into suprachoroidal space to enhance targeting ability within the SCS by 
controlling the movement of the particles.  
Suprachoroidal delivery is very attractive method to deliver drugs because it 
allows us to put therapeutics exactly adjacent to the targeting tissues like ciliary body and 
choroid, which are the sites of action for serious vision threatening diseases such as 
glaucoma, wet age related macular degeneration, diabetic retinopathy, and uveitis[147, 
148] 11, 12. Currently, sustained release formulations are delivered as an implant that are 
placed in vitreous, a chamber at the center of the eye, which often requires surgical 
procedures to insert the implants.  
Microneedle provides simple safe, and reliable way to deliver polymeric 
controlled release formulations in minimally invasive way. Currently, retinal specialists 
give millions of intravitreal injections per year at the same site of injection located 2-5 
mm from the limbus[158, 159]. This similarity makes the injection procedure 
straightforward for an ophthalmologist. SCS injection using microneedle also carries less 
safety concerns because it only penetrates partially into the eye. On the other hand, 
intravitreal injection requires needle to penetrate across entire layer of the eye. 
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This study demonstrates for the first time that simple polymeric excipient 
formulations can be used to target specific regions within the suprachoroidal space using 
simple polymeric formulations to control the mobility of polymeric particles. This highly 
targeted delivery reduces the amount of drug administered. This opens up an opportunity 
for us to deliver longer sustained release formulation, due to reduction in required dosage. 
This can save money, due to lower drug costs. This can also improve safety and patient 
acceptance, due to reduced side effects. For example, intravitreal administration of 
steroids causes unwanted contact with lens and promotes the formation of cataract in 
6.6% of the patients [151]. By targeting drug delivery to the targeting site, side effects 
caused at off-target sites of action can be reduced. SCS delivery could deliver high 
particles concentration that could potentially deliver many months of sustained release 
formulation. 
Many in situ gelling polymers such as solvent removal, temperature, pH, or light 
mediated introduces potentially toxic materials (organic solvents), and complexities to the 
procedure. By simply utilizing non-Newtonian fluids to modulate fluid’s viscosity at high 
shear (when flowing through the needle) and low shear rate (when inside the tissue) 
provides much simpler pharmaceutical formulations for clinicians to use. Polysaccharides 
provide excellent biocompatibility and are already used in many pharmaceutical 
formulations. But most importantly, targeting within the SCS can be easily done by 
utilizing simple materials that are already approved by FDA. We believe SCS injection can 
be easily adopted because its similarity to currently used intravitreal administration. 
Currently, intravitreal injections are done by retinal specialist million times per year at the 
pars plana located 2-5 mm from the limbus. SCS delivery requires an injection at same site. 
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This makes the SCS injection procedure very simple and straightforward for an 
ophthalmologist to perform. In addition, targeting SCS can be easily done by simple 
polymeric formulation, which does not require any complex process or equipment. Highly 
reduced dosage requirement and ability to delivery high polymeric concentration using 
microneedles could potentially deliver many months of sustained release formulation. In 
related work accessing the suprachoroidal space, microneedles have been used for 
hundreds of suprachoroidal injections in rabbits and to a lesser extent in pigs, and were 
recently reported for use in four human subjects[66, 109, 134, 160-162]. We believe 
ability to target different regions in the uvea could provide more effective therapies for 
many vision-threatening diseases.  
 
4.5. CONCLUSION 
This study demonstrates that polymeric particles as large as 10 µm can be targeted 
to the site of injection and throughout entire layer of the choroid using simple polymeric 
excipient formulation. In vivo study showed that materials exhibit strongly non-
Newtonian properties at low shear stress can be used to slow down the expansion of the 
embedded polymeric particles at the site of injection up to 2 months. We also 
demonstrated that high molecular weight compounds that does not show non-Newtonian 
properties at lower shear rate are capable of enhancing the spreading of up to 10 µm sized 
polymeric particles to cover entire layer of the choroid using single injection. This study 
shows for the first time that simple polysaccharides excipient formulation can to use to 
target specific regions within the suprachoroidal space using microneedles in minimally 
invasive way. Further study is required to optimize characteristics of excipient 
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formulations and injection parameters such as molecular weights, concentration, and 
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5 TARGETED DELIVERY OF ANTI-GLAUCOMA DRUGS TO THE 
SUPRACILIARY SPACE USING MICRONEEDLES 
	  
5.1. INTRODUCTION 
Glaucoma is the second leading cause of blindness worldwide [1, 20], even 
though well-established pharmacological treatments are available. Poor patient 
compliance plays a significant role in the loss of the vision in patients with glaucoma. 
The estimated compliance with use of topical eye drops is as low as 56% [163], which 
shows that patients cannot manage daily eye drops well. Patients are required to administer 
eye drops one or more times per day because systemic therapy (e.g., by oral delivery, 
which typically has higher compliance [163-165]) with most anti-glaucoma drugs causes 
unacceptable side effects [166, 167]. 
Although topical drops administer drug to the eye, they nonetheless are poorly 
targeted to their specific sites of action within the ocular globe [47]. Topical delivery is 
highly inefficient and requires frequent dosing to overcome poor drug absorption and 
rapid clearance. Bioavailability of eye drops is typically well below 5%, and what little 
drug enters the eye is delivered non-specifically throughout the anterior segment with 
only a small fraction of the drug reaching its site of therapeutic action [45-47]. In the case 
of many anti-glaucoma drugs, that site of therapeutic action is the ciliary body [110, 111]. 
Also, the poorly targeted nature of eye drops leads to extensive systemic exposure, which 
causes up to 8-53% of glaucoma patients taking topical anti-glaucoma drugs to 
experience side effects [149, 150]. This poor patient compliance and low bioavailability 
of glaucoma drugs creates the need for a better delivery method [3]. 
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In this study, we introduce supraciliary delivery to target drug administration 
adjacent to the ciliary body to maintain high therapeutic drug levels at the site of 
pharmacologic action in the targeted tissue. This targeting of the ciliary body can be 
accomplished by administering drug into the supraciliary space, which is a potential 
space located below the sclera and above the choroid and ciliary body that can expand to 
accommodate a fluid or drug formulation. We and others have previously reported on the 
use of the suprachoroidal space for drug targeting to the choroid and adjacent retina to 
reach posterior segment targets [62, 65, 67, 109, 134, 168-170]. Here, we access the 
ciliary body in the anterior segment by injecting drug into the most anterior portion of the 
suprachoroidal space, which we are calling the supraciliary space. By localizing the drug 
in the supraciliary space, we expect to achieve high drug levels locally in the adjacent 
ciliary body.  
Previous studies have accessed the suprachoroidal space to demonstrate highly 
targeted and reliable delivery to this space and effective drug treatment with no major 
safety concerns in animal models and human subjects [62, 65, 67, 109, 134, 168-170]. 
Researchers have accessed the suprachoroidal space using surgically introduced catheters 
and conventional hypodermic needles, but more recently our group introduced the use of 
microneedles as a simple and reliable method of suprachoroidal injection that is expected 
to be suitable for use as a rapid office procedure [67]. A first-in-humans study recently 
demonstrated injection of bevacizumab into the suprachoroidal space of four human eyes 
using a microneedle [109]. In the present study, we have adapted this method to target 
injection into the supraciliary space, as the first study exploring the use of this potential 
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space to deliver therapeutics immediately adjacent to the ciliary body and the first study 
to examine pharmacodynamics of this delivery method.  
This study seeks to assess the efficacy of supraciliary delivery using a hollow 
microneedle in the rabbit and compare that to conventional topical delivery. We carried 
out this assessment by delivering anti-galucoma drugs to the supraciliary space and 
measuring reduction in intraocular pressure (IOP) over time compared to topical delivery 
of the same drugs. The drugs used in this study –  sulprostone and brimonidine – both 
have sites of action in the ciliary body [110, 111], which suggests that supraciliary 
targeting should be beneficial.  
Sulprostone is a prostaglandin analogue that has been shown to lower IOP in the 
rabbit [171-174], but is not used in humans to treat glaucoma. Latanoprost, travoprost, and 
bimatoprost are prostaglandin analogues in common human clinical use [175, 176], but 
rabbits respond poorly to these drugs [177-183]. We therefore used sulprostone as a model 
prostaglandin analogue with similar pharmacological properties to other prostaglandin 
analogues [110, 111]. Our other drug, brimonidine, is in common clinical use for anti-
glaucoma therapy and is active in the rabbit eye too. In this study, we measured IOP in 
the New Zealand White rabbit after bolus injection of sulprostone and brimonidine at a 
range of different doses and compare their responses to topical eye drops to test the 
hypothesis that highly targeted delivery of anti-galucoma drugs to the supraciliary space 





5.2. MATERIALS AND METHODS 
5.2.1. Microneedle Fabrication and Formulation 
Microneedles were fabricated from 33-gauge stainless steel needle cannulas (TSK 
Laboratories, Tochigi, Japan). The cannulas were shortened to approximately 700-800 
µm in length and the bevel at the orifice was shaped using a laser (Resonetics Maestro, 
Nashua, NH), as described previously [66, 69]. The microneedles were electropolished 
using an E399 electropolisher (ESMA, South Holland, IL) and cleaned with deionized 
water. Sulprostone (Cayman Chemical, Ann Arbor, MI) and 0.15% brimonidine tartrate 
ophthalmic solution (Alphagan® P, Allergan, Irvine, CA) were diluted in Hank’s 
Balanced Salt Solution (HBSS, Cellgro, Manassas, VA). For topical delivery, the final 
concentration was 0.05 mg/ml sulprostone or 1.5 mg/ml brimonidine tartrate. For 
supraciliary injection, the solution was diluted to a range of drug concentrations and 
included 2% carboxymethylcellulose (CMC, Sigma–Aldrich, St. Louis, MO) to increase 
viscosity and thereby improve localization of the drug at the site of injection.  
 
5.2.2. Anesthesia and Euthanasia 
All studies used New Zealand White rabbits of mixed gender weighing between 
3-4 kg (Charles River Breeding Laboratories, Wilmington, MA). All of the animals were 
treated according to the ARVO statement for the Use of Animals in Ophthalmic and 
Vision Research. For supraciliary injections and for application of topical eye drops, 
rabbits were anesthetized using 0.5 – 3.0% isoflurane, unless otherwise noted. The 
isoflurane percentage was slowly increased from 0.5% up to 2.5% or 3.0% for 15 min. To 
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achieve longer-lasting anesthesia for the supraciliary and intravitreal safety studies 
measuring IOP immediately after injection, anesthesia was achieved using subcutaneous 
injection of a mixture of ketamine (25 mg/kg) and xylazine (2.5 mg/kg). This 
ketamine/xylazine dose was also used during initial studies screening suitable anesthetics 
for this study. Proparacaine (a drop of 0.5% solution) was given 1 – 3 min before each 
injection to locally numb the ocular surface. Animals were euthanized with an injection 
of 150 mg/kg pentobarbital into the ear vein. 
 
5.2.3. Pharmacodynamics studies 
For supraciliary injection, a microneedle was attached to a 50 µl gas-tight glass 
syringe containing either (i) a placebo formulation of HBSS or (ii) a drug formulation 
containing a specified concentration of either sulprostone or brimonidine tartrate. The 
eyelid of the rabbit was pushed back and the microneedle was inserted into the sclera 3 
mm posterior to the limbus in the superior temporal quadrant of the eye. A volume of 10 
µl was injected within 5 s and the microneedle was removed from the eye 15 s later to 
reduce reflux of the injected formulation. Topical delivery of sulprostone and 
brimonidine was achieved by administering an eye drop into the upper conjunctival sack. 
IOP was measured hourly for 9 h after drug administration, as described below. Each 
treatment involved application of just one dose of one drug either topically or by 
supraciliary injection in one eye. After a recovery period of at least 7 days, rabbits were 
used for additional experiments, alternating between the left and right eyes.   
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5.2.4. Safety Studies 
Supraciliary injections of either 10 µl or 50 µl of HBSS were performed as 
described above. Intravitreal injection was performed by inserting a 30-gauge hypodermic 
needle across the sclera 1.5 mm posterior to the limbus in the superior temporal quadrant 
of the eye. A volume of 50 µl HBSS was injected within 5 s and the needle was removed 
from the eye 15 s later to reduce reflux. IOP was measured periodically for 1 h after 
injection, as described below. 
 
5.2.5. Intraocular Pressure Measurement 
IOP was measured with a hand-held tonometer (TonoVet, icare, Vantaa, Finland) in 
the awake, restrained rabbit. Topical anesthesia was not necessary for the measurement and 
no general anesthetic or immobilizing agent was used because the procedure is not 
painful. We made every effort to avoid artifactual elevation of IOP by avoiding topical 
anesthesia and by careful and consistent animal handling during each measurement. Each 
rabbit was acclimatized to the IOP measurement procedure for at least 3 days to obtain a 
stable background IOP reading. 
 
5.2.6. Calculation of Area Under the Curve And Equivalent Dosage  
The pharmacodynamic effect of each treatment was characterized by determining 
the area under the curve of the temporal profile of intraocular pressure by numerically 
integrated using the trapezoidal rule[184]. This pharmacodynamic area under the curve 
(AUCPD) is a measure of the strength and duration of the treatment on IOP. To make the 
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AUCPD calculation, IOP readings were normalized to the IOP reading prior to the treatment. 
The obtained value of AUCPD had units of mm Hg-hr and a negative value (because the 
drugs under study all lowered IOP). However, the negative values were changed to positive 
values for better representation of the data.  
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Where IOP(ti) in mm Hg represents the IOP value measured at time ti in seconds. 
An equivalent dosage comparison between topical and supraciliary delivery was made 
using the following equation, where D is the dose administered and the subscripts SC and 
topical mean suprachoroidal injection and topical administration, respectively.  
 




         (2) 
 
5.2.7. Statistical Analysis 
Three replicate pharmacodynamics and safety experiments were done for each 
treatment group, from which the mean and standard error of mean were calculated. 
Experimental data were analyzed using two-way analysis of variance (ANOVA) to 
examine the difference between treatments. In all cases, a value of p < 0.05 was 




5.3.1. Effect Of Anesthesia On Transient IOP Change 
Before studying the effect of supraciliary targeting of anti-glaucoma drugs, we 
needed to identify a general anesthetic that does not create artifactual changes in rabbit 
IOP over the time scale of the experiment. We first tested subcutaneous injection of 
ketamine/xylazine, which produced deep anesthesia for approximately 2 h. This 
anesthetic also produced significant ocular hypotension that lasted for 4 – 5 h, with a 
peak IOP decrease of approximately 5 mm Hg at 1 h after injection of the anesthetic, 




Figure 5.3.1.1. Effect of general anesthetics on IOP in the rabbit eye. (a) 
Ketamine/xylazine (25/2.5 mg/kg) was administered by subcutaneous injection. (b) 
Isoflurane (up to 3%) was administered by inhalation for 15 min. IOP was measured in 




We then tested isoflurane, which was administered by inhalation of an escalating 
dose over 15 min. Anesthesia quickly set in upon initiation of the isoflurane dose and 
quickly reversed upon discontinuation of the isoflurane dose. During the 15 min of 
isoflurane administration, IOP was elevated by almost 5 mm Hg, but quickly returned to 
normal after isoflurane administration was stopped, and remained unchanged for 9 h after 
that (Fig. 5.3.1.1.b). We believe the initial, transient ocular hypotension may have been 
due to both the pharmacological effect of the anesthetic, as well as the psychological 
effect (i.e., startling the rabbit) of administering the inhaled anesthetic.  
We conclude from these studies that isoflurane is a suitable anesthetic for the 
pharmacodynamic experiments in this study, because isoflurane’s effects on IOP reversed 
within 15 – 30 min, which is fast enough to permit hourly measurements of IOP without 
significant artifact from the anesthetic. However, for the safety experiments in this study 
in which IOP is measured multiple times within 1 h, the rapidly changing effects of 
isoflurane on IOP would significantly affect IOP measurements. For that reason, we used 
ketamine/xylazine for the safety study, because the effect of the anesthetic on IOP was 
relatively small during the first 10 min when the most critical IOP measurements were 
made in the safety study.  
 
5.3.2. Anti-Glaucoma Drugs in the Normotensive Rabbit Model 
To test our hypothesis regarding drug targeting via the supraciliary space, we next 
needed to identify anti-glaucoma drugs that have pharmacological action at the ciliary 
body and reduce IOP in the normotensive rabbit model. Our candidates were 
prostaglandin analogues, adrenergic agonists and beta-blockers that have their 
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pharmacological site of action at the ciliary body [110, 111, 166]. Our first choice was 
prostaglandin analogues because they are widely used in human clinical medicine [175, 
176], including for glaucoma treatment [166]. Latanoprost, travoprost, and bimatoprost are 
commonly used prostaglandin analogues [175, 176], but rabbits respond poorly to these 
drugs [177-183]. We tested latanoprost in our rabbit model, but observed no change in IOP 
at the standard human dose of 2.5 µg (data not shown).  
We therefore used sulprostone as a model prostaglandin analogue with its site of 
pharmacological action to the ciliary body [110, 111] and an ocular hypotensive effect 
well documented in literature [172, 174]. A single topical eye drop of 2.5 µg of 
sulprostone gave a maximum IOP decrease of almost 5 mm Hg at approximately 2 h after 
drug administration (Fig 5.3.2.1.). Ocular hypotension in the treated eye lasted up to 5 h. 
We did not observe changes in IOP in the contralateral (i.e., untreated) eye. Responses of 
the contralateral eyes were statistically insignificant compared to the negative control 




Figure 5.3.2.1. Effect of topical sulprostone administration on IOP in the rabbit eye. A 
single drop containing 2.5 µg sulprostone was administered to one eye. IOP was then 
followed for 9 h in both the treated eye and the untreated/contralateral eye. Data points 
represent the average ± SEM (n = 4). 
 
To more fully test our hypothesis, we decided to study a second drug that lowers 
IOP by a different mechanism in the ciliary body as well, and selected brimonidine, an 
adrenergic agonist that is widely used in clinical glaucoma therapy. While the 
pharmacology and site of action causing an IOP response to brimonidine is species 
dependent [185], adrenergic agonists have a site of action in the ciliary body in both the 
rabbit [185] and human [186-188]. A previous study demonstrated α2-adrenoceptor 
agonism by showing that pretreating the eye with α2-selective antagonists inhibited the 
IOP response to brimonidine in rabbits [189].  
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We found that topical administration of a single drop (75 µg) of brimonidine 
produced a peak IOP reduction of approximately 5 mm Hg at 3 h after drug 
administration, which slowly returned to normal within 7 h (Fig. 5.3.2.2. a). Topical 
administration of three drops (225 µg) of brimonidine initially increased IOP, but then 
reduced it by approximately 6 mm Hg at 2 h after drug administration, which slowly 
returned to normal within 9 h (Fig. 5.3.2.2. b). This initially elevated IOP response can be 
explained by the known effect of brimonidine to increase IOP at high concentrations and 




Figure 5.3.2.2. Effect of topical brimonidine administration on IOP in the rabbit eye. A 
single drop containing (a) 75 µg or (b) 225 µg brimonidine was administered to one eye. 
IOP was then followed for 9 h in both the treated eye and the untreated/contralateral eye. 
Data points represent the average ± SEM (n = 3). 
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It is notable that the contralateral (untreated) eye also experienced elevated IOP 
with faster kinetics and similar magnitude (Fig. 5.3.2.2.), presumably due to systemic 
distribution of brimonidine. The slower kinetics in the treated eye could be explained by 
a local brimonidine concentration that was initially too high and only after some 
clearance of the drug reached the optimal concentration for IOP reduction, whereas the 
contralateral eye had lower brimonidine concentration from the start due to the non-
targeted systemic delivery route. Previous research also showed decreased IOP in the 
contralateral eye in rabbits, which was produced due to systemic administration after 
administering brimonidine at high concentrations in the treated eye and was reflected by 
plasma concentrations high enough to activate central α2-adrenoceptors [190] and 
cardiovascular changes [185].  
 
5.3.3. Microneedles For Targeted Delivery To the Supraciliary Space 
Our next step was to demonstrate targeted injection into the supraciliary space 
using a microneedle. Because the thickness of sclera above the suprachoroidal space in 
the rabbit is ~500 µm [191], we prepared microneedles measuring 700 – 800 µm to be 
inserted to the base of the sclera and in that way target injection into the suprachoroidal 
space. The needles were longer than the thickness of the sclera to account for the 
overlying conjunctiva and for the expected deformation of the sclera during insertion of 
the microneedle. Fig. 5.3.3.1. shows a representative microneedle prepared for 




Figure 5.3.3.1. Hollow microneedle (at arrow) measuring 720 µm in length shown next to 
a liquid drop of approximately 50 µl volume from a conventional eye dropper. 
 
Previous studies making injections in this way have targeted the suprachoroidal 
space with the objective of having the injected formulation flow away from the site of 
injection and travel circumferentially around the eye for broad coverage of the choroidal 
surface, especially toward the posterior pole. In this study, we had the opposite objective. 
Our goal was to localize the injected formulation at the site of injection immediately 
above the ciliary body and minimize flow to other parts of the eye.  
To accomplish this goal, we increased the viscosity of the injected formulation by 
adding 2% w/v CMC. The viscosity of this solution at rabbit body temperature of 39°C 
was 80.5 ± 3.7 Pa-s at a shear rate of 0.1 s-1, which is approximately 80,000 times more 
viscous than water at room temperature. Injection of this high-viscosity formulation into 
the rabbit eye using a microneedle was able to localize the injection near the site of 
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injection. As shown in Fig 5.3.3.2.a, the dye injected in this way spread over an area 
within just a few millimeters from the site of injection. The degree of this spread 
depended on the amount of fluid injected, such that there was more spread when larger 
volumes were used (data not show).  
 
 
Figure 5.3.3.2. Supraciliary targeting of injections using a high-viscosity formulation 
injected using a microneedle. (a) Injection of 10 µl of red-fluorescent particles (1 µm 
diameter, 0.5% w/v) into the rabbit eye ex vivo spread only a few millimeters from the site 
of injection. The whole eye was imaged by a digital camera 60 min after injection. (b) 
Injection of 50 µl of red-fluorescent particles (1 µm diameter, 0.5% w/v) into the rabbit eye 
ex vivo was localized to the supraciliary space, directly above and adjacent to the ciliary 
body. The eye was frozen immediately after injection, prepared as frozen sections and 
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imaged by brightfield microscopy. (c) Injection of 30 µl of red-fluorescent microparticles 
(10 µm diameter, 0.5% w/v) into a human cadaver eye was localized to the supraciliary 
space. The eye was fixed in formalin immediately after injection, prepared as frozen 
sections and imaged by overlaying a brightfield microscopy image to show ocular anatomy 
with a fluorescent microscopy image of the same histological section showing fluorescent 
particles. 
 
Histological examination demonstrated that the injection was localized to the 
supraciliary space. As shown in Fig. 5.3.3.2. b, the injected dye can be seen in the 
expanded supraciliary space bounded by the ciliary body on the lower anterior boundary, 
the choroid on the lower central and posterior boundary and the sclera on the upper 
boundary of the rabbit eye. In Fig 5.3.3.2. c, a similar experiment was conducted in a 
human eye, which similarly shows supraciliary localization of the injected fluorescent 
particles. While the supraciliary space is significantly expanded immediately after 
injection when these tissues were frozen for analysis, we believe that this space closes 
down again as fluid is absorbed, based on our unpublished data on suprachoroidal 




Figure 5.3.3.3. Effect of supraciliary injection on IOP in the rabbit eye. A single injection 
of 10 µl of a 2% w/v solution of CMC was administered to one eye. IOP was then followed 
for 9 h in both the treated eye and the untreated/contralateral eye. Data points represent the 
average ± SEM (n = 3). 
 
We also determined the possible effect of supraciliary injection of 2% CMC on 
IOP over the course of our experiments. As shown in Fig. 5.3.3.3., there was no apparent 
effect of this injection on IOP at the hourly timepoints over the course of a 9 h study. A 
two-way ANOVA comparing the isoflurane-only group (Fig. 5.3.1.1.) to the data in Fig. 
5.3.3.3. showed no statistically significant difference with p-values of 0.885 and 0.084 for 




5.3.4. Pharmacodynamics of Sulprostone After Supraciliary Delivery 
Having completed the initial experiments on anesthesia, topical delivery and 
supraciliary targeting, we were now able to test the central hypothesis of this study 
regarding the effects of anti-glaucoma drugs targeted to the supraciliary space. We 
therefore injected sulprostone into the supraciliary space over a range of doses (0.05 µg – 
0.0005 µg) in rabbits. Starting with a pre-treatment IOP of 10-11 mm Hg, supraciliary 
delivery of sulprostone at a dose of 0.05 µg (i.e., a dose 50 times lower than the topical 
dose shown in Fig. 5.3.2.2.) produced an IOP decrease of ~6 mm Hg within 1 h that 
persisted at that level for at least 9 h (Fig. 5.3.4.1. a). IOP was similarly decreased in the 
contralateral eyes, but to a lesser extent. At this dose, responses of the contralateral eyes 
were significantly different compared to placebo treatment (p = 0.006). Supraciliary 
delivery of 0.005 µg sulprostone (i.e., a dose 500 times lower than the topical dose) 
produced a peak IOP drop of ~4.5 mm Hg at 1 h after drug administration (Fig. 5.3.4.1. 
b). IOP increased over time, but ocular hypotension persisted for the full 9 h in the treated 
eye. Responses of the contralateral eyes were not significantly different from placebo 
treated eyes (p = 0.53). Supraciliary delivery of 0.0005 µg sulprostone (i.e., a dose 5,000 
times lower than the topical dose) did not produce a significant reduction in IOP in the 
treated eyes (p = 0.68) or the contralatereral eyes (p = 0.18) (Fig. 5.3.4.1. c).  
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Figure 5.3.4.1. Effect of supraciliary injection of sulprostone on IOP in the rabbit eye. A 
single injection of (a) 0.05 µg, (b) 0.005 µg and (c) 0.0005 µg sulprostone was 
administered to one eye. IOP was then followed for 9 h in both the treated eye and the 
untreated/contralateral eye. Data points represent the average ± SEM (n = 3-4). 
 
Overall, sulprostone was found to lower IOP in a dose-dependent manner (Fig. 
5.3.4.1.a). Based on a rough comparison, topical delivery of 2.5 µg sulprostone and 
supraciliary delivery of 0.005 µg sulprostone showed similar levels of initial IOP 
reduction, although the effect lasted longer after supraciliary delivery. To provide a more 
quantitative measure of the supraciliary dose equivalent to topical delivery, we 
determined and compared the AUCPD for the pharmacodynamic data in the topical and 
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supraciliary treated eyes (Fig. 5.3.4.2. b). Comparison of these values gave a ratio of 
1122, which indicates that the supraciliary dose needed to achieve a similar 
pharmacodynamic response was ~1100 fold less than for topical delivery. We believe 
that this dramatic dose sparing was achieved by highly targeted delivery of sulprostone to 
its site of action in the ciliary body. 
 
 
Figure 5.3.4.2. Comparison of IOP drop caused by supraciliary delivery versus topical 
delivery of sulprostone. (a) Data from Figs. 5.3.2.1. and 5.3.4.1. are graphed together to 
show the dose-response relationship after supraciliary delivery and to facilitate comparison 
with topical delivery in the treated eyes. (b) Pharmacodynamic area under the curve 
(AUCPD) after supraciliary delivery in treated and contralateral eyes, and in comparison 




5.3.5. Pharmacodynamics Of Brimonidine After Supraciliary Delivery 
To assess the generality of dose sparing by targeting anti-glaucoma drugs to the 
supraciliary space, we carried out similar experiments to study supraciliary delivery of 
brimonidine over a range of concentrations (0.0015 µg – 0.15 µg) in rabbits. Similar to 
sulprostone, brimonidine produced a concentration-dependent drop in IOP at doses much 
lower than used for topical delivery. Supraciliary delivery of brimonidine at a dose of 15 
µg (i.e., a dose 5 times lower than the topical dose shown in Fig. 5.3.2.2. a) produced an 
IOP decrease of ~5 mm Hg within 1 h that persisted at that level for about 9 h (Fig. 




Figure 5.3.5.1. Effect of supraciliary injection of brimonidine on IOP in the rabbit eye. A 
single injection of (a) 15 µg, (b) 0.15 µg, (c) 0.0015 µg and (d) 0.00015 µg brimonidine 
was administered to one eye. IOP was then followed for 9 h in both the treated eye and the 
untreated/contralateral eye. Data points represent the average ± SEM (n = 3). 
 
Supraciliary delivery of 0.15 µg brimonidine (i.e., a dose 500 times lower than the 
topical dose) produced a peak IOP drop of ~3.5 mm Hg at 1 h after drug administration 
that persisted at that level for about 7 h (Fig. 5.3.5.1. b). The contralaterial eye showed a 
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similar, but smaller drop in IOP. Supraciliary delivery of both 0.015 µg and 0.0015 µg 
brimonidine (i.e., doses 5,000 and 50,000 times lower than the topical dose, respectively) 
showed no significant IOP changes in treated (p=0.91) and contralateral eyes (p=0.056). 
Supraciliary delivery of brimonidine reduced IOP in a dose-dependent matter (Fig. 
5.3.5.1. a). Compared to topical delivery of 75 µg of brimonidine, a 500-fold lower dose 
of 0.15 µg of brimonidine by supraciliary delivery showed a similar duration and 
magnitude of ocular hypotension (Fig. 5.3.5.1. a). By calculating AUCPD values (Fig. 
5.3.5.1. b), we estimated the supraciliary dose needed to get a similar pharmacodynamic 
response was 504-fold less than topical delivery. It is notable that in the rabbit model 
studied here, decreased IOP was seen both in the treated eyes and to a lesser extent in the 
contralateral eyes (Fig. 5.3.5.1.). Ocular hypotension in contralateral eyes is believed to 
be due to systemic absorption [192]. Similar contralateral responses were also observed 




Figure 5.3.5.2. Comparison of IOP drop caused by supraciliary delivery versus topical 
delivery of brimonidine. (a) Data from Figs. 5.3.2.2.a and 5.3.5.1. are graphed together to 
show the dose-response relationship after supraciliary delivery and to facilitate comparison 
with topical delivery in the treated eyes. (b) Pharmacodynamic area under the curve 
(AUCPD) after supraciliary delivery in treated and contralateral eyes, and in comparison 
with topical delivery. Data are from Figs. 5.3.2.2. a and 5.3.5.1. AUCPD was calculated 
using Eq. 1. 
 
5.3.6. Safety of Microneedle Injection into the Supraciliary Space  
Injections into the supraciliary space using microneedles were well tolerated and 
no injection-related complications were observed, such as bleeding or squinting. After 
injection, the needle insertion site was not visually apparent on the conjunctival surface, 
indicating only very minor trauma (Fig. 5.3.6.1.). We did not observe any inflammation, 
redness, or pain-related response after the injection. No apparent vision loss was observed 
in any of the rabbits. To further assess safety, we measured IOP elevation associated with 
supraciliary and intravitreal injection. Note that this is the short-lived elevation in IOP 
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caused by the injection itself (as opposed to the longer-term IOP reduction caused by the 
anti-glaucoma drugs presented above). For this study, ketamine/xylazine was used for 
general anesthesia because it provides a relatively steady IOP between 1 h and 2 h after 
injection (Fig. 5.3.1.1.). Rabbits given an intravitreal injection of 50 µl of HBSS 1 h after 
induction of anesthesia were found to have a peak IOP increase 36±1 mm Hg due to the 
injection (Fig. 5.3.6.2.). IOP then decreased exponentially until it stabilized after 30-40 min 
after the injection. This is similar to what is seen in human patients, where intravitreal 
injection can increase IOP by ~30 mm Hg [193]. Considering intravitreal injection is well 
tolerated in human patients using just topical anesthesia and is safely performed millions 





Figure 5.3.6.1. Representative images of a rabbit eye (a) before (b) 1 hour after and (c) on 
day after supraciliary injection of the placebo formulation (2% CMC). All images are of the 
same rabbit eye. The lower row of images shows magnified views of the injection site of 
the eyes shown in the upper row of images. 
 
We similarly injected 50 µl of a 2% CMC formulation into the supraciliary space of 
the rabbit eye and observed a transient increase in IOP that peaked at 35±3 mm Hg and 
decayed in under 1 h, which is similar to the effects of conventional intravitreal injection 
(Fig. 5.3.6.2.). We also injected 10 µl of formulation into the supraciliary space and found 
the peak IOP increase was 5±1 mm Hg, which then disappeared within 20 min. 
Considering the similar magnitude and kinetics of IOP change by these intravitreal and 
supraciliary injection, we hypothesize that the safety profile of supraciliary delivery may 
be similar to that of intravitreal injection. In fact, supraciliary injection may be safer than 
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intravitreal injection, considering that intravitreal and supraciliary injections are 
performed at the same site of the eye (i.e., pars plana) [194], but supraciliary injection 
uses a needle that penetrate an order of magnitude less deeply into the eye.  
 
 
Figure 5.3.6.2. IOP increase due to injection of 50 µl of HBSS into the intravitreal space 
(IVT) and 10 µl and 50 µl of 2% carboxymethylcellulose placebo formulation (CMC) into 
the supraciliary space (SCS). 
 
5.4. DISCUSSION 
In current therapy, anti-glaucoma drugs with a site of action in the ciliary body 
are almost always given by topical eye drops. This approach has a very low 
bioavailability, with typically less than 5% of the applied drug being absorbed into the 
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eye and only a tiny fraction of that reaching its therapeutic target in the ciliary body [195, 
196]. As a result, eye drops must be given at least daily and there can be side effects from 
systemic delivery of the poorly absorbed drug [197, 198]. This study introduces the idea 
of targeting the ciliary body by injection into the adjacent supraciliary space. We 
accessed this space located just a few hundred microns below the conjunctival surface by 
using a hollow microneedle designed to be just long enough to penetrate to the base of 
the sclera. Injection at this site filled the supraciliary space with a formulation designed 
with high viscosity that inhibited its flow away from the site of injection, thereby creating 
a depot next to the ciliary body. When anti-glaucoma drugs – sulprostone and 
brimonidine – we injected in this way, they were able to reduce IOP at doses three orders 
of magnitude lower than those required for similar pharmacodynamics using topical eye 
drops. These results show the highly targeted nature of supraciliary delivery and suggest 
opportunities to improve glaucoma therapies. Targeted delivery reduces the amount of 
drug administered. This can save money, due to lower drug costs. This can also improve 
safety and patient acceptance, due to reduced side effects. For example, incidence of iris 
darkening in patients receiving prostaglandin analogues is as high as 35% [199, 200] and 
brimonidine causes dry mouth in 33% of patients [167]. By targeting drug delivery to the 
ciliary body, side effects caused at off-target sites of action can be reduced.  
Targeted delivery also facilitates development of sustained-release therapies that 
eliminate the need for patients to comply with daily eye-drop regimens. For example, 
brimonidine is used clinically at a daily topical dose of 75 µg given 3 times per day [201]. 
The daily dose of brimonidine administered to the supraciliary space appears to be 
approximately 500 times less than the topical dose. This means that the supraciliary daily 
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dose is believed to be 0.45 µg and a six-month supply would be 81 µg. A six-month 
polymeric sustained-release system with a 5% drug loading would have a mass of 1,620 
µg, which corresponds to a volume of 1.6 µl (assuming a density of 1 g/ml). A 10% w/v 
suspension of microparticles containing a six-month supply of sustained-release 
brimonidine would have a volume of 16 µl. This small volume can easily be injected into 
the supraciliary space, given that much larger volumes were successfully injected in this 
study.  
If this vision for sustained-release drug therapy can be realized, it could have a 
dramatic effect on patient compliance with glaucoma therapy. Current therapy requires 
many patients to administer eye drops on at least a daily basis. Compliance with such 
dosing schedules is very low, in the range of 56% [163]. Many glaucoma patients visit 
their ophthalmologists every six months for routine exams. In this way, glaucoma 
patients could receive supraciliary injections of sustained-release medication during their 
regular doctor’s visits and thereby eliminate the need for compliance with topical eye 
drop therapy.  
From a practical standpoint, we believe that supraciliary injections could be 
relatively easily introduced into clinical practice. Currently, retina specialists give 
millions of intravitreal injections per year at the pars plana located 2-5 mm from the 
limbus [158, 159]. Supraciliary targeting requires placement of microneedles at the same 
site, which should be straightforward for an ophthalmologist to do. Assuring 
microneedles go to the right depth at the base of the sclera is determined by microneedle 
length, which is designed to match scleral thickness. In related work accessing the 
suprachoroidal space, microneedles have been used for hundreds of suprachoroidal 
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injections in rabbits and to a lesser extent in pigs, and were recently reported for use in 
four human subjects [66, 109, 134, 160-162].  
  
5.5. CONCLUSION 
This study provides the first demonstration of supraciliary injection that targeted 
delivery of anti-glaucoma drugs to their site of action in the ciliary body. Choice of the 
right anesthetic facilitated these studies, as both isofluorane and ketamine/xylazine affected 
IOP, but with different pharmacodynamics. Choice of the right drug was also important; 
we studied sulprostone, which is a model prostaglandin analogue drug that works in rabbits, 
and brimonidine, which is an α2-adrenergic agonist drug that works in both rabbits and 
humans, and shows significant effects in the contralateral eye after unilateral drug 
administration in the rabbit. We found that microneedles enable targeted injection into the 
supraciliary space and that anti-glaucoma drugs administered in this way show three-order-
of-magnitude reduction in dose for similar reductions in IOP compared to topical delivery. 
The rabbits tolerated supraciliary injections well, with no adverse events or notable 
findings regarding safety. We conclude that targeted drug delivery to the supraciliary space 
using a microneedle enables dramatic dose sparing of anti-glaucoma therapeutics compared 




6 PARTICLE-STABILIZED EMULSION DROPLETS FOR 
GRAVITY-MEDIATED TARGETING IN THE POSTERIOR 
SEGMENT OF THE EYE 
 
6.1. INTRODUCTION 
Age related macular degeneration (AMD) is the third leading cause of blindness. 
It is estimated that more than 1.8 million individuals in United States are afflicted by wet 
age-related macular degeneration (AMD) and that number expected to grow to almost 3 
million by 2020 [21, 22]. Only within the past decade many revolutionary therapeutics 
agents became available to effectively mange chorioretinal diseases [29, 30]. However, 
there are no clinically used methods to deliver therapeutics to the targeting part of the eye 
to obtain best treatment efficacy. Currently, free drug formulations are administered by 
intravitreal injection, a hypodermic needle injection in the center of the eye. And 
sustained release formulations are delivered as an implant that are placed in vitreous, a 
chamber at the center of the eye. However, it is often overlooked that the targeting sites 
for many of the posterior diseases are not at the center but at the back of the eye in the 
layer of choroid, mid layer in the back of the eye [147, 148]. Furthermore the non-
targeted nature of intravitreal administration allows possible adverse events and toxicity 
in the surrounding tissue. For example, intravitreal administration of steroids causes 
unwanted contact with lens and promotes the formation of cataract in 6.6% of the patients 
[151]. In addition, delivering sustained release formulation often requires surgical 
procedures to insert the implants. A novel delivery method that can deliver controlled 
release formulation in a non-invasive manner specifically to the back of the eye to 
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maintain high therapeutic levels of a drug in the choroid, a targeting region of the eye, 
should provide more effective therapy for back of the eye diseases. 
 
 
Figure 5.3.6.1. Schematic showing the structure of PEDs (a). Schematics showing 
injection of PEDs into suprachoroidal space of the eye. Prior to injection procedure, 
suprachoroidal space is collapsed and does not exist (b). Following the injection, 
suprachoroidal space expand (c) and give space or PEDs to migrate towards back of the 
eye (d). After several minutes suprachoroidal space will clear aqueous phase to hold the 




The targeting within the eye can be accomplished by administering drugs into the 
suprachoroidal space (SCS). The SCS is a potential space located between sclera and 
choroid that can expand to accommodate a fluid or drug formulation. The location of the 
SCS adjacent to the target site for treatment of chorioretinal diseases like wet AMD and 
diabetic retinopathy may provide higher drug levels in the target tissues. For this reason, 
the SCS represents a promising new site of administration for treatment many ocular 
diseases. 
Microneedle’s microscopic size makes it an ideal device to deliver materials into 
suprachoroidal space. Microneedles allows precise placement of the needle tip right at the 
suprachoroidal space. The suprachorodal space is right above the choroidal blood bed, 
which is targeting site for many uveoretinal diseases. Suprachoroidal space can expand to 
incorporate large amount of polymeric particle formulations [66]. This method can 
potentially used to deliver many months of controlled release formulation. Using just 
aqueous formulation, the injected micro and nanoparticles covers a portion of the 
suprachorodial space but not well targeted to specific regions within suprachoroidal space.  
To improve on this technique, we have developed formulation to deliver the 
nanoparticles specifically to posterior segment of the eye using emulsion droplets. These 
emulsion droplets have high-density perflurodecalin liquid at the core and are stabilized 
using nanoparticles. Perfluorodecalin has approximately twice the density of water and 
this density difference will be used to create mobility inside the suprachoroidal space in 
the direction of gravity. The nanoparticles have a dual purpose to carry drugs and 
stabilize the emulsion droplets. For the first time, this study presents a method to target 
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particles specifically to the back of the eye using particle stabilized emulsion droplets 
(PEDs).  
The concept of using gravity and density differences to enhance targeting ability 
of injected particles has been previously studied before in creating floating particles for to 
enhance gastric retention, and pulmonary delivery [70-72]. Both approaches are similar 
in a sense that the key parameter that was considered was density difference between 
particle and the carrier fluid. To our knowledge this is first study to create and study 
high-density emulsions for ophthalmic drug delivery to the posterior of the eye. We 
examined the capabilities and critical parameters of stabilized emulsion droplets (PEDs) 
that could affect the mobility of PEDs inside the suprachoroidal space. Overall, this study 
shows that the gravity-mediated delivery can provide targeted delivery of nanoparticles to 
the ciliary body and macula using minimally invasive microneedle device. 
	  
6.2. MATERIALS AND METHODS 
6.2.1.  Microneedle fabrication 
Metal microneedles were fabricated from 30-gauge needle cannulas (Becton 
Dickinson, Franklin Lakes, NJ). The cannulas were shortened to approximately 600-700 
µm in length and the bevel at the orifice was shaped using a laser (Resonetics Maestro, 
Nashua, NH). The microneedles were electropolished using an E399 electropolisher 





Figure 6.2.1.1. Hollow microneedle (a) and a hollow microneedle mounted on a leur 
adapter attached to a syringe (b) 
 
 
6.2.2.  Ex vivo injection procedure 
Whole rabbit eyes were purchased (Pel-Freez Biologicals, Rogers, AR) with the 
optic nerve attached. Eyes were shipped on ice and stored wet at 4°C for up to 2 days 
prior to use. Eyes were allowed to come to room temperature, and any fat and 
conjunctiva were removed to expose the sclera. A catheter was inserted through the optic 
nerve into the vitreous and connected to a bottle of Hank’s Balanced Salt Solution (HBSS, 
Corning Cellgro, Manassas, VA) raised to a height to generate internal eye pressure of 10 
mmHg. 10 mm Hg was used to mimic the lowered intraocular pressure in rabbit with 
general anesthesia. The microneedle was attached to a gas tight glass syringe containing 
the formulation to be injected. Microneedle was then inserted perpendicular to the sclera 
tissue 3 mm posterior from the limbus. Volume of 200 µL was injected within 3 seconds 
and additional 30 seconds was allowed before removing the microneedles from the eye to 
prevent excessive reflux. 
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6.2.3.  In vivo microneedle injection 
Microneedle injection was done under systemic anesthesia (subcutaneous 
injection of a mixture of ketamine/xylazine/ace promazine - 17.5/8.5/0.5 mg/kg). 
Proparacaine (a drop of 0.5% solution) was given two to three minutes before 
microneedle injection as a temporary analgesia. The microneedle was attached to a gas 
tight glass syringes containing the formulation to be injected. For an SCS injection, the 
eyelids of the rabbit were pushed back and the microneedle was inserted into the sclera 3 
mm past the limbus in the superior temporal quadrant of the eye. Volume of 200 µl was 
injected within 5 seconds and additional 60 seconds was allowed before removing the 
microneedles from the eye to prevent excessive reflux. Both eyes on each animal were 
used for the experiment. We waited 30 minutes after the injection to give enough time for 
the PEDs to completely settle down and all the aqueous formulation to dissipate out of 
the suprachoroidal space. After waiting 30 minutes, if needed injection to other side of 
the eye was done. All experiments were carried out using New Zealand white rabbits and 
animals were euthanized with an injection of pentobarbital through the ear vein. 
 
6.2.4.  Particle stabilized emulsion droplet Formulation 
 Carboxylate-modified non-biodegradable, fluorescently tagged, 2 wt. % of 200 
nm diameter polystyrene nanoparticles (Invitrogen, Carlsbad, CA) was diluted in BSS to 
obtain 0.6%, 0.4%, and 0.2% solution. Obtained solution was then mixed at 7:3 ratio by 
volume with perfluorocarbon (perfluorodecalin, Sigma-Aldrich, St. Louis, MO) and it 
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was homogenized (PowerGen 700, Fisher Scientific Pittsburgh, PA) at setting 5 for 20 
seconds to form particle stabilized emulsion droplets (PEDs). After forming PEDs, 
aqueous phase was removed and replaced with 1% polyvinyl alcohol (PVA, Sigma-
Aldrich) in BSS solution. The solution was then filtered through various sizes (11, 20, 30, 
41 µm) of nylon net filters (Millipore, Billerica MA) to obtain desired emulsion droplet 
sizes. Multiple images of the PEDs were taken using microscope and the PEDs size 
distribution was measured using ImageJ (US National Institutes of Health, Bethesda, 
MD). The concentration of the PEDs was determined by volume of settled PEDs per 
volume of aqueous phase (1% PVA). All the particle size were prepared using the 
concentration of 50 µl of PEDs/1 mL of solution.   
 
6.2.5.  Tissue processing and measurement of florescent intensity 
After the suprachoroidal injection, eyes were snap frozen in an isopropyl alcohol 
(2-isopropanol, Sigma Aldrich) bath, which was cooled in dry ice. After the eyes were 
completely frozen, they were removed and eight radial cuts were made from the posterior 
side towards anterior segment to the cornea. After making eight cuts around the ocular 
globe, each of cut was peeled away outward exposing the inside of the eye. This makes 
eyes into flat mount like configuration visually exposing the inner side and the injected 
dyes in naked eyes. Bright field and florescent images of the inside of the eyes were 
imaged to visualize the distribution of fluorescent nanoparticles. Brightfield images were 
taken using digital camera (Cannon Rebel T1i, Melvile, NY) and florescent images were 
taken using a fluorescence microscope (Olympus SZX16, Center Valley, PA). Each of 
the eight pieces was then divided into additional four pieces. Approximate distance from 
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the pars plana to back of eye ranged from 1.2 – 1.4 mm. The cuts were made 3, 6, and 9 
mm away from the pars plana, where suprachoroidal space starts, and resulting total of 32 
pieces from each eye. Individual pieces were paired into 4 quadrants resulting in 16 vials 
containing 2 pieces of the tissue and BSS solution. Ocular tissues were then homogenized 
(Fisher Scientific PowerGen) to extract injected non-biodegradable florescent 
nanoparticles. Aqueous part of the solution was pipetted out into 96 well plates to 
measure fluorescent signal intensity (Synergy Microplate Reader, Winooski, VT). 
 
 
Figure 6.2.5.1. (a). Picture of posterior segment of the eye showing the radial cuts and 
how ocular tissues were divided into 4 radial quadrants. Picture of an ocular globe 
showing the 3 mm cuts from the anterior to posterior segment (b). 
 
6.2.6.  Particle Stabilized Emulsion droplet Fall Time Measurement 
Prepared PEDs were put into the clear glass vial and vigorously shaken before the 
start of recording the movement of PEDs using digital camera (Cannon Rebel T1i). Green 
light bulb (Feit Electric, Pico Rivera, CA) was used to excite the florescent nanoparticles 
surrounding the PEDs and red camera filter (Tiffen red filter, Hauppauge, NY) was 
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mounted on a digital camera to visualize the movement of PEDs. Height of the solution 
was measured and the time it takes for all the PEDs to submerge to the bottom of the vial 
was measured.  
 
6.2.7.  Particle Stabilized Emulsion droplet Fall Time Modeling 
𝐹!"# = 𝐹! − 𝐹! − 𝐹!                       (1)  
𝜌!𝑉!  𝑥!! 𝑡 = 𝜌!𝑉!𝑔 + 𝜌!𝑉!𝑔 + 6𝜋𝜂𝑟𝑥!(𝑡)            (2)  
 
Where, 𝐹! is Stokes drag force, 𝐹! is buoyancy force, 𝐹! is gravitational force, 
𝐹!"# is the net force, 𝜌! is density of the PED, 𝜌! is density of a carrier fluid (i.e., water), 
𝑉! is the displacement volume of a PED, 𝑉! is the displacement volume of the carrier 
fluid, 𝑔 is gravitation acceleration, 𝜂 is the viscosity of the carrier fluid, 𝑟 is the radius of 
a PED, and 𝑥(𝑡) is height as a function of time.   
 
6.2.8.  Ultrasound measurement 
Ultrasound scanner (UBM Plus, Accutome, Malvern, PA) was used to monitor the 
expansion of the suprachoroidal space. Ultrasound scanning probe was positioned 45 
degrees away from the injection site radially was constantly measured for before and 10 
minutes after the injection procedure. 
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6.2.9. Statistical Analysis 
Three replicate pharmacodynamics and safety experiments were done for each 
treatment group, from which the mean and standard deviation were calculated. 
Experimental data were analyzed using one-way analysis of variance (ANOVA) was 
used to examine the difference between treatments. In all cases, a value of p < 0.05 was 
considered statistically significant. 
 
6.3. RESULTS  
6.3.1. Fabrication and characterization of particle-stabilized high-density emulsion 
droplets (PEDs) 
We sought to create high-density particles that enables targeting posterior of the 
eye by gravity. In order to advance currently available treatment of once a month 
hypodermic needle injection in to the center of the eye, we wanted deliver sustained 
release formulation. Therefore, we sought to deliver polymeric particles for long-term 
release of a drug. It would be ideal if we could design a polymeric particle that have a 
high density and also capable of encapsulating and releasing drugs. However, it could be 
a difficult task to creating such a novel material and additional toxicology studies are 
required to be applicable in human use. It would be beneficial to create formulation based 
on existing FDA approved materials to avoid possible toxicity associated with novel 
biomaterial. Therefore, we decided to create a particle with two different materials for 
independently optimizing the density and drug encapsulation and release. We sought to 
create emulsion droplets with high-density liquid core and polymeric particles as a 
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stabilizer for drug encapsulation (Fig. 5.3.6.1.a). We wanted to use polymeric particles as 
a drug carrier because its capability to easily tailor properties, release profile, and has 
been studied extensively in a literature. And we selected a high gravity material as 
perfluorodecalin due to its high density (1.9 g-cm-3) and is considered as a most 
commonly used perfluorocabons in vitreoretinal surgeries [202]. Instead of conducting 
studies using drug-loaded particles, we decided to use commercially available non-
biodegradable polystyrene florescent particles to easily trace and quantify targeting 
efficiency of the injected PEDs. It is well cited in literature that hydrophilic surfaces are 
necessary for stabilizing the oil in water emulsion droplets [203]. Although pure 
polystyrene nanoparticles are hydrophobic, we used particles with carboxylate 
modification on the surface of the particles with a zeta potential of -47.5±6.07mV, which 
is essential to form oil in water emulsion droplets [204]. We aimed to create PEDs using 
largest size of particles to maximize the loading of a drug. However, we failed to create 




Figure 6.3.1.1. (a) Diameter of the emulsion droplet as a function of nanoparticle 
concentration in aqueous phase. (b) Size distribution of emulsion droplet as a function of 
nanoparticle concentration in aqueous phase. 
 
Next, we wanted to make PEDs of different sizes in order to optimize size for 
gravity-based targeting in the eye. We achieved this by varying the concentration of 
nanoparticles in the solution when fabricating the PEDs.  As shown in Fig. 6.3.1.1.a PED 
size decreased with increasing nanoparticle concentration, which is consistent with 
observations by others [205]. Increase in nanoparticle’s concentration allows higher 
surface area coverage of the emulsion droplets resulting smaller size of PEDs. However, 
PED populations produced in this way were highly poly-disperse (see Fig. 6.3.1.1.b). To 
provide more uniform particle size distributions, we separated the PEDs into size 
fractions by passing sequentially through nylon net membrane filters of 11, 20, 30 and 40 
µm pore size, which produced PED populations of 14 ± 4.3 µm, 25 ± 6.0 µm and 35 ± 
7.5 µm diameter (Figs. 6.3.1.2.a - 6.3.1.2.c). As shown in Fig. 5.3.6.1., each PED 
contained a non-fluorescent interior composed of perfluorodecalin and a film of red-
fluorescent nanoparticles around the outer surface. The high-density of the PEDs was 
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demonstrated by rapid settling under gravity, as shown in Fig. 6.3.1.2.d. The ability to 
separate the different PED sizes by filtration shows that the PEDs were mechanically 
strong enough to withstand the separation process.  
 
 
Figure 6.3.1.2. Confocal microscope image of 14 µm (a), 25 µm (b), and 35 µm (c) 
PEDs. The scale bar indicates 40 µm. Florescent image of 35 µm PEDs immediately after 




PEDs were designed to fall quickly in the eye due to gravity, where larger 
particles should fall faster than smaller particles due to their increased mass. To 
determine the fall time of the PEDs in water, which provides an initial estimate of fall 
time inside the eye after injection, both experimental measurements and theoretical 
calculations were performed. The measured time for PEDS of 14 µm, 25 µm and 35 µm 
diameter to fall to the bottom of a vial filled with water to a height of 1 cm (see Materials 
and Methods) was 93±3 s, 54±5 s, and 31±2.4 s, respectively. A simple force balance to 
model the process predicted fall times of 104 s, 32 s and 16 s, respectively. The 
discrepancies between measured and calculated values may be due to variation of the size 
of and interaction between the PEDs, as well as the subjective nature of experimentally 
determining when all PEDs settled to the bottom by visualization. In any case, settling 




Figure 6.3.1.3. Measured time it take for the emulsion droplets to fall 1 cm in 1% PVA 
solution. 
 
6.3.2. Use of gravity to target PEDs within the rabbit eye ex vivo  
Before conducting in vivo experiments, we tested our hypothesis that deposition 
of PEDs in eye can be directed by gravity by injecting PED suspension in the 
suprachoroidal space of the rabbit eye ex vivo and changing orientation of the eye with 
respect to gravity. We first targeted delivery to the anterior portion of the suprachoroidal 
space by positioning the eye with the cornea facing down. The distribution of PEDs after 
injection was determined by dividing the suprachoroidal space into four antero-posterior 
quadrants (Fig. 6.2.5.1.a). We found that 59% of the injected PEDs were targeted to the 
most anterior quadrant, located between the limbus and the site of injection 3 mm back 
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from the limbus (Fig. 6.3.2.1.b and 6.3.2.1.d). Particle concentration decreased further 
back in the eye, with just 2.3% of PEDs in the most posterior quadrant located 9 mm or 
further back from the limbus. There was a statistically significant decrease in PED 
concentration moving posteriorly within the suprachoroidal space (one-way ANOVA, p = 
0.0002). This shows significant targeting of the PEDs to the anterior portion of the 
suprachoroidal space.  
We next targeted delivery to the posterior portion of the suprachoroidal space by 
positioning the eye with the cornea facing up. In this case, 73% of the injected PEDs 
were located in the two most posterior quadrants and just 8.1% was in the most anterior 
quadrant (Fig. 6.3.2.1.c and 6.3.2.1.d). There was a statistically significant increase in 
PED concentration moving posteriorly within the first three quadrants of the 
suprachoroidal space (one-way ANOVA, p = 0.02). This shows significant targeting of 
the PEDs to the posterior portion of the suprachoroidal space and, when compared with 
the anteriorly targeted data, demonstrates the gravity-mediated mechanism of the 
targeting.  
Finally, we were interested to characterize the radial distribution of PEDS to the 
left and right of the injection site. As shown in Fig. 6.3.2.1.e, the large majority of the 
particles were located in the upper radial quadrants immediately to the left and right of 
the injections site (i.e., between -90° to 0° and 0° to 90°) and very little reached the lower 
radial quadrants (i.e., between -180° to 90° and 90° to 180°). There was no significant 
difference between the particle concentration in each of these quadrants as a function of 
eye orientation (i.e., cornea up versus cornea down, p > 0.10). This is expected, because 
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radial movement is in the direction perpendicular to the gravitational field, meaning that 




Figure 6.3.2.1. Image showing how the ocular tissue was dissected (a). Injection 
of 35 µm of PEDs into a rabbit eyes showing localization to the anterior segment (b) and 
posterior segment (c) by changing orientation of the eye. The eyes were enucleated and 
frozen immediately and imaged by overlaying a brightfield microscopy image to show 
ocular anatomy with a fluorescent microscopy image of the same eye showing 
fluorescent nanoparticles. (e) Distribution of percentage of particles towards posterior 
segment for two different orientations (cornea down and up). (e) Radial distribution of 
percentage of particles away from the injection site. The arrow indicates the injection site.  
* - Indicates statistical significance between two different orientations. 
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6.3.3. 2.2. Use of gravity to target PEDs within the rabbit eye in vivo  
Next, that we repeated the injection of 35 µm PEDs in in vivo to verify if ex vivo 
results can be translated in vivo eyes. Comparison between the PEDs in each antero-
posterior quadrant (0 – 3, 3 – 6, 6 – 9, and 9 – rest mm) of the suprachoroidal space after 
injection in vivo was insignificantly different from injection ex vivo (one-way ANOVA, p 
> 0.8, 0.7, 0.9, 0.7, respectively see Fig. 6.3.3.1.). The radial distributions (–180° to –90°, 
–90° to 0°, 0° to 90°, and 90° to 180°) for in vivo and ex vivo eyes also showed no 
significant differences (one-way ANOVA, p > 1, 0.8, 0.9, 0.9, respectively). These data 
show a good correlation between ex vivo and in vivo injections and demonstrate the use 
of gravity to target PEDs within the living rabbit eye.  Gravity-based targeted relies on 
the use of PEDs with a density greater than water. Therefore, to further assess the role of 
gravity to target movement of PEDs inside the suprachoroidal space, we carried out an 
identical experiment using fluorescently tagged polystyrene microparticles with a 32 µm 
diameter and a density of 1.05 g-cm-3 in comparison to PEDs with a 35 µm diameter and 
perflurodecalin density of 1.92 g-cm-3. The injection conditions in both cases were the 
same, such as volume (200 µL), concentration (50 µl / 1 ml) and cornea up. As shown in 
Fig. 6.3.3.2., injection of 32 µm polystyrene fluorescent microparticles resulted in 13±5% 
of polystyrene particles reaching the most posterior quadrant. In contrast, 2.5 times more 
of the PEDs reached the most posterior quadrant (i.e., 32±12%). One-way ANOVA 
analysis shows a statistically significant increase in PED concentration moving 
posteriorly within the first three quadrants of the suprachoroidal space (one-way 
ANOVA, p = 0.0020). In contrast, there was no statistically significant change in 
concentration of the polystyrene microparticles within the first three antero-posterior 
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quadrants (one-way ANOVA, p = 0.99). The radial distributions (–180° to –90°, –90° to 
0°, 0° to 90°, and 90° to 180°) showed no significant differences (one-way ANOVA, p = 
0.34, 0.34, 0.026, and 0.14, respectively) between PEDs and polystyrene microparticles.  
 
 
Figure 6.3.3.1. (c) Distribution of percentage of PEDs towards posterior segment. (d) 
Radial distribution of percentage of PEDs away from the injection site. The arrow 





Figure 6.3.3.2. (a) Injection of 32 µm of polystyrene microparticles into a rabbit eyes 
showing distribution of microparticles. The eyes were enucleated and frozen immediately 
and imaged by overlaying a brightfield microscopy image to show ocular anatomy with a 
fluorescent microscopy image of the same eye showing fluorescent nanoparticles. (b) 
Injection of 35 µm of PEDs into a rabbit eyes showing localization to the posterior 
segment. The eyes were enucleated and frozen immediately and imaged by overlaying a 
brightfield microscopy image to show ocular anatomy with a fluorescent microscopy 
image of the same eye showing fluorescent nanoparticles. (c) Distribution of percentage 
of microparticles towards posterior segment. (d) Radial distribution of percentage of 
PEDs away from the injection site. The arrow indicates the injection site. *- Indicates 
statistical significance between 32 µm micronparticles and PEDs. 
 
6.3.4. Retention of PEDs at the site of targeted delivery 
To be most valuable, PEDs should not move around inside the eye after the 
targeted injection. We hypothesized suprachoroidal space will immediately expand after 
the injection but will collapse back to its normal position as fluid dissipates and this will 
immobilize the PEDs. To test this hypothesis, we injected 35 µm PEDs to left eyes and 
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waited 5 days and immediately before sacrificing the rabbits, we injected PEDs to the 
right eyes to compare the distribution of PEDs to left eyes of the same animal. As shown 
in Fig. 6.3.4.1., the distribution of the particles showed similar trend of increase in 
amount of PEDs towards the posterior segment. Statistical analysis (one-way ANOVA) 
between each tissue segments (0 – 3, 3 – 6, 6 – 9, and 9 – rest mm) showed significant 
difference only in 6 – 9 mm segment with p-values of 0.79, 0.89, 0.032, and 0.11, 
respectively. The radial distributions (–180° to –90°, –90° to 0°, 0° to 90°, and 90° to 
180°) for eyes at 0 days and 5 days after injection showed no statistical (one-way 
ANOVA) difference with p-value of 0.27, 0.36, 0.27, and 0.32, respectively. We 
therefore conclude PEDs can be targeted to regions of the suprachoroidal space during 
injection and then can be retained at the site of targeted delivery afterwards. Additional 
studies will be needed to further assess this retention of PEDs over longer times and, 





Figure 6.3.4.1. Injection of 35 µm PEDs into a rabbit eyes in vivo showing localization to 
the posterior segment after 0 day (a) and 5 days (b). The eyes were enucleated and frozen 
immediately and imaged by overlaying a brightfield microscopy image to show ocular 
anatomy with a fluorescent microscopy image of the same eye showing fluorescent 
nanoparticles. (n = 3-4) (c) Distribution of percentage of PEDs towards posterior segment. 
(d) Radial distribution of percentage of PEDs away from the injection site. The arrow 
indicates the injection site. *- Indicates statistical significance between day 0 and 5. 
 
6.3.5. Effect of PED size on gravity-mediated targeting 
Next we sought to measure the mobility of PEDs inside the suprachroidal space as 
a function of PED size. We therefore injected PEDS of 14 µm, 25 µm and 35 µm 
diameter (Fig. 6.3.1.2.) into the suprachoroidal space and measure the extent of posterior 
targeting with the cornea facing up in the rabbit eye in vivo. Our data indicate that the 
larger PEDs are better in targeting posterior segment (Fig. 6.3.5.1.). We believe this 
variation is due to variation of the fall time for different size of the PEDs (Fig. 6.3.1.3.). 
Although the trends suggest the 35 µm particles have a better targeting ability towards 
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the macula, statistical analysis (one-way ANOVA) showed no significance. The radial 
distributions for 14 and 25 µm only showed statistical (one-way ANOVA) difference in –
90° to 0° and 0° to 90°, segment with p-value of 0.005 and 0.01, respectively. However, 
no significance in radial distribution was found between 35 µm PEDs and other sizes. We 
conclude that 35 µm PEDs are optimal for gravity-mediated targeting among the PED 
sizes tested. It is possible that still-larger PEDS would provide even better targeting by 
gravity. However, if the PEDs become too large their movement in the suprachoroidal 







Figure 6.3.5.1. Injection of 14 (a), 25 (b), and 35 µm (c) of PEDs into a rabbit eyes 
showing distribution. The eyes were enucleated and frozen immediately and imaged by 
overlaying a brightfield microscopy image to show ocular anatomy with a fluorescent 
microscopy image of the same eye showing fluorescent nanoparticles. (d) Distribution of 
percentage of PEDs towards posterior segment. (e) Radial distribution of percentage of 
PEDs away from the injection site. The arrow indicates the injection site. *- Indicates 
statistical significance between 14 and 25 µm PEDs. 
 
   
6.3.6. Kinetics of suprachoroidal space expansion and collapse 
An important parameter that could affect the movement of PEDs in 
suprachoroidal space is the time it takes for suprachoroidal space to collapse down after 
the injection. Since the time-required PEDs to migrate to posterior segment strongly 
depend on spatial expansion and collapse time of suprachoroidal space after the injection, 
therefore we sought to further explore the physical changes to understand the movement 
of PEDs inside the suprachoroidal space. The targeting efficiency of the PEDs of 
different particle suggests that particle size has an impact on the mobility of the PEDs 
inside the suprachoroidal space. In another word, the drop time of the PEDs will impact 
the targeting efficiency (Fig. 6.3.5.1.). We hypothesized that after the injection into 
suprachoroidal space, it temporarily expands to incorporate injected fluid until the fluid 
quickly dissipates away within 30 seconds (approximate drop time for 35 µm PEDs).  
We therefore determined the time it takes for fluid to dissipate from 
suprachoroidal space by two methods. First, we measured IOP over time after injection as 
an indirect measure of suprachoroidal space expansion. As shown in Fig. 6.3.6.1.a, IOP 
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increased by 72 mm Hg upon injection, substantially dropped within 5 min and then 
returned to baseline IOP within 20 min. The initial increase in IOP is believed to be due 
to introduction of additional fluid into the eye. This effect is seen after intravitreal 
injection as well [206]. The decay in IOP is believed to be due to clearance of the fluid 
from the eye. These data therefore suggest that fluid that is injected into the 
suprachoroidal space is cleared from that space largely within 5 min and completely 
within 20 min. This provides an estimate for the time window during which PEDS can be 
targeted by gravity within the suprachoroidal space before that space closes down and 
entraps the PEDs.  
The second method we used to assess the kinetics of suprachoroidal space 
expansion and collapse used ultrasound imaging to directly measured the height of the 
suprachoroidal space over time at a single location. Measurements by ultrasound at a 
location 45° away radially from the injection site showed immediate expansion and 
substantial collapse within tens of seconds. We believe this rapid collapse of the 
suprachoroidal space could explain why 35 µm PEDs showed better movement towards 
the posterior segment of the eye compared to 14 µm PEDs (Fig. 6.3.5.1.). The 35 µm 
PEDs showed as much as 50% injected PEDs 9 mm away from the ciliary body 5 days 




Figure 6.3.6.1. Intraocular pressure change after injecting 200 µl of BSS into 
suprachoroidal space (a). Ultrasound images of the rabbit eye showing kinetics of the 
suprachoroidal space expansion and subsequent collapse after injecting 200 µl of BSS 
into suprachoroidal space (b-f). The ultrasound probe was positioned 45 degrees away 





The idea of creating density differences to enhance drug delivery has been used 
before in creating floating particles to enhance gastric retention and pulmonary delivery 
[70-72]. Both approaches are similar in a sense that the key parameter that was 
considered was density difference between particle and the carrier fluid. Creating 
emulsion droplet using solid particles has been studied since the Pickering [82] originally 
recognized the role of insoluble solid particles in stabilizing emulsion droplet. Since then, 
many investigators have studied the stability of particle-stabilized emulsion droplets [83-
85]. Particle stabilized emulsion droplet has many uses in food industry, cosmetic 
industry, pharmaceutical industry, petroleum industry, and in agricultural industry [83]. 
Particle stabilized emulsion droplets could be stabilized using particles such as silica, 
clays, titanium dioxide, latex and many others [87-90]. Previously, particle stabilized 
emulsion droplets has been studied in drug delivery applications [86]. To our knowledge 
this is the first study to use gravity and particle stabilized emulsion droplets to enhance 
targeting in the eye.  
Currently, the conventional drug delivery methods, such as topical and intravitreal 
administration, cannot target specific locations within the ocular globe and that is 
especially the case for delivering controlled release formulation. Suprachoroidal space is 
a unique space that gives us an ability to deliver large amount of therapeutic formulations 
in a confined space within the ocular globe. The targeting ability of PEDs will provide us 
with power to deliver polymeric nanoparticles into posterior segment. 
Age related macular degeneration is a disease affects older generation and results 
in a vision loss due to damage in central part of the retina called the macula. Age related 
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macular degeneration is the third leading cause of blindness. It is estimated that more 
than 1.8 million individuals in United States are afflicted by wet age-related macular 
degeneration (AMD) and that number expected to grow to almost 3 million by 2020 [21, 
22]. Choroidal neovascularization (CNV) is the underlying disease of age-related macular 
degeneration and diabetic retinopathy. However, there are no clinical used methods to 
deliver therapeutics to the targeting tissue layer, which is choroid. Currently 
pharmacological treatment for age-related macular degeneration requires once a month 
injection into anterior chamber of the eye for six months or as a necessary basis. 
Suprachoroidal injection of allows extremely targeted delivery method to deliver 
therapeutics to the site of action. The combination of suprachoroidal injection and PEDs 
will allow delivery of controlled release formulation in an extremely targeted manner. 
This targeted approach should lead to significant amount of dose sparing, which in turn, 
reduces side effect due to low required dose.  
For targeting posterior segment of the eye, we envisioned, patients receiving the 
injection lying down on a bed and wait certain period of time for the PEDs to settle and 
the suprachoroidal space to collapse to hold the PEDs at the posterior segment. 
Emulsions could be made using various emulsifiers such as amino acids, phospholipids, 
or solid particles. Using solid particles loaded with drug as an emulsifier simplifies the 
design of the emulsion droplets compared to using phospholipids and allows controlled 
release of a drug. In addition, unnecessary excipient formulation could be avoided by 
using only essential materials that could act both as emulsifier and drug carrier. 
Perfluorocarbons is the material that has been used in the food and drug administration 
(FDA) approved ultrasound contrast agents [207] and ophthalmic vitreoretinal 
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surgeries[208]. Since the introduction by Haidt in 1982 [209] perfluorocarbons have been 
widely used in ophthalmic surgeries [202]. Perfluorodecalin, the material that is used in 
this study, is considered as most commonly used perfluorocabons in vitreoretinal 
surgeries along with perfluorohexyloctane and perfluoroperhydrophenanthrene, and 
octafluoropropane [202]. 
In current clinical practice, retina specialists give millions of intravitreal 
injections per year at the pars plana located 2-5 mm from the limbus [158, 159]. 
Suprachoroidal injection requires placement of microneedles at the same site, which 
should be straightforward for an ophthalmologist to do. Assuring microneedles go to the 
right depth at the base of the sclera is determined by microneedle length. While scleral 
thickness varies among eyes, experience in rabbits, pigs and humans shows that for a 
given species, a single microneedle length generally works in all eyes to target the 
suprachoroidal space. Ocular anatomy is accommodating because shallow injections can 
punch through scleral tissue to reach the supraciliary space and deep injections do not 
enter choroid because of its deformability. Microneedles have been used for hundreds of 
suprachoroidal injections in rabbits, a dozen in pigs and four in human subjects with 
extremely reliable targeting [66, 109, 134, 160-162]. Highly targeted delivery into 
suprachoroidal space could enable us to deliver single dosing of anti-VEGF therapeutics 
every 3-6 months or more, which could dramatically increase patient compliance.  
Our research group at Georgia Institute of Technology used microneedles for 
injection into the suprachoroidal space for delivery to the posterior segment in >200 rabbits. 
All injections were successfully targeted to the suprachoroidal space and there were no 
significant adverse reactions [66-68, 134, 161]. Clearside Biomedical, a company that has 
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licensed our technology, has received IND approval from FDA based on a published 90-
rabbit GLP study of safety, which likewise showed no significant adverse effects or lasting 
IOP changes [162]. The company has also published data from four human patients 
receiving suprachoroidal injection of Avastin using a microneedle, which was well 
tolerated with no serious adverse events over a two-month monitoring period[109]. Based 
on this experience with suprachoroidal injection to the posterior segment, we believe that 




This study demonstrates that polymeric nanoparticles can be targeted to the 
posterior of the ocular globe using gravity mediated delivery methods via suprachoroidal 
delivery using hollow microneedles. In vivo study showed that 35 µm particle stabilized 
emulsion droplets can specifically target 73% of injected particles towards back of the 
ocular globe. We also demonstrated that by orienting the eyes in different orientation, 
allows us to mobilize emulsion droplets in the direction of gravity to target different 
locations within the ocular globes. Orienting the eye’s visual direction in the same 
direction as the gravity (e.g. surface of the cornea facing downward) allows more than 
85% of injected particles to stay within 6 mm of the pars plana. This study shows for the 
first time that gravity mediated method can be used to target specific locations within the 
ocular globe using microneedles in minimally invasive way. Future study is required to 
optimize many injection parameters such as injection volume, optimize size of emulsion 





Current treatment of ocular disorders in the eye is constrained by inefficient drug 
delivery methods, since topical application and even intraocular injection is not targeted 
enough to the site of action. In addition, many intraocular injections lead to safety 
concerns. It is especially challenging if the molecules we want to deliver are 
macromolecules such as protein or sustained release formulation. It makes the treatment 
much more challenging if the targeting tissue is at the back of the eye such as in age 
related macular degeneration (AMD). In this study, microneedles were tested in 
conjunction with novel formulations to provide targeted drug delivery into the eye guided 
by the previous advancement in ocular drug delivery.  
The first part of the work introduced a minimally invasive strategy for delivering 
protein therapeutics to the cornea. In this work, we showed that highly targeted 
intracorneal delivery of bevacizumab using a coated microneedle allowed dramatic dose 
sparing compared to subconjunctival and topical delivery in an injury-induced 
neovascularization model. Eyes treated with 4.4 µg of bevacizumab using microneedles 
reduced neovascularization compared to the untreated eye by 65% (day 10) to 44% (day 
18). Eyes treated with 2500 µg of bevacizumab using subconjunctival injection gave the 
same results as the eyes treated with 4.4 µg of bevacizumab-coated microneedles. While 
eyes treated with 52500 µg of bevacizumab by eye drops three times per day for 14 days 
reduced neovascularization area compared to the untreated eye by 44% (day 10) to 6% 
(day 18). Safety study showed microneedle did not affect corneal transparency and 
microanatomical structures. As a result, these data could be used to design an effective 
device for delivering bevacizumab and other protein therapeutics into the cornea. 
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In second part the study, we developed novel formulations to immobilize or to 
enhance the spreading of injected polymeric particles. Study showed stronly non-
Newtonian materials were capable of slowing down the movement of particles inside the 
suprachoroidal space for period of 60 days. Study also showed that the high molecular 
weight polymers and weakly non-Newtonian materials generated movement of imbedded 
particles inside the suprachoroidal space and were capable of covering 100% of the 
suprachoroidal space using a single injection. Overall, this study demonstrates for the 
first time that simple polymeric excipients could be used to control the movement of 
polymeric particles inside the suprachoroidal space. 
In the third part of the study, we showed that highly targeted delivery of anti-
glaucoma drugs to the supraciliary space using a hollow microneedle allows dramatic 
dose sparing of the drug compared to topical eye drops. The supraciliary space is the 
most anterior portion of the suprachoroidal space located below the sclera and above the 
choroid and ciliary body. We showed that isoflurane, rather than ketamine/xylazine as the 
anesthetic, did not effect the IOP change in the time scale of an hour, thereby minimizing 
artifacts from anesthesia. We showed supraciliary delivery of sulprostone reduced IOP 
unilaterally in a dose-related response. Pharmacodynamics analysis showed 
approximately 1100-fold dose sparing of sulprostone by supraciliary injection in 
comparison with topical administration at the conventional human dose. We also showed 
supraciliary delivery of brimonidine reduced IOP bilaterally in a dose-related response. 
Pharmacodynamics analysis showed approximately 500-fold dose sparing of brimonidine 
by supraciliary injection in comparison with topical administration at the conventional 
human dose. A safety study showed that the kinetics of IOP elevation immediately after 
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supraciliary and intravitreal injection of placebo formulations were similar. Overall, we 
demonstrated targeted delivery in this way could increase patient compliance and safety 
by achieving significant dose sparing which allow a single injection to contain enough 
drugs for long-term sustained delivery and reduces side effects. 
In the fourth and final part of the study, we showed particle stabilized high-
density emulsion droplets (PEDs) could be used to enhance targeting of various locations 
within the eye via suprachoroidal space injection. Microneedles were shown to deliver 
nanoparticles preferentially towards the posterior of the eye using high-density PEDs into 
the suprachoroidal space of rabbits. Up to 35 µm sized PEDs were injected into 
suprachoroidal space of the eye and were able to deliver particles preferentially towards 
back of the eye by showing 2.5 times increase in particle concentration at the posterior of 
the eye compared to 32 µm polystyrene particles. In addition, by comparing the eyes 
immediately and 5 days after the injection, we demonstrated that the PEDs stay at the 
posterior segment up to 5 days. We were able to confirm the expansion of the 
suprachoroidal space immediately after the injection, to incorporate the injected fluid but 
then collapse down within several minutes by looking at real time ultrasound images. 
This study demonstrates for the first time that high-density PEDs could be used to 
preferentially deliver nanoparticles to posterior of the eye. 
Overall, this work introduces novel approaches to enhance targeting of 
macromolecules to cornea, ciliary body, choroid, and back of the eye using microneedles 
as a drug delivery platform. This work showed methods to effectively deliver 
macromolecules to the targeted tissues and demonstrated that the highly targeted drug 
delivery method using microneedles provided the following expected advantages: (i) 
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bioavailability approaching 100% by delivering drugs directly to the targeting tissue, (ii) 
reduce side effects due to low dosage requirement by delivering more drugs to the 
targeting site, (iii) improved patient compliance by administering longer controlled-
release formulation which is not possible without highly targeted delivery, (iv) in a 
minimally invasive way using microneedles.  
Studies in this thesis show some of the first methods to achieve targeted delivery 
of sustained-release formulation at various locations within the eye. We believe this work 
can provide an alternative modality to deliver pharmacotherapies and controlled release 
formulations in a highly targeted way to reduce side effects and increase patient 
compliance. We expect clinicians to make sound decision to utilize both existing and 
microneedle based delivery to tailor the treatments to fit the need for different patients’ 
life style and symptoms. We also believe this work could provide a tool for both present 
and future research to develop new pharmacotherapies that might require significant 
targeting to achieve its full efficacy. Blindness results in devastating impact on peoples’ 
lives and we believe microneedle based drug delivery methods could one day be used to 








The research presented here represents some of the first studies to develop novel 
techniques to deliver dugs to specific locations within the eye. In addition, studies here 
demonstrate the advantages of highly targeted ocular drug deliver using microneedles. 
Conventional ocular drug delivery methods often deliver drugs to the whole ocular globe 
and are not capable of delivering drugs to specific locations within the ocular globe. The 
results from this work demonstrate the capabilities of microneedle-based drug delivery 
methods to deliver therapeutics to various locations within the eye in minimally invasive 
and highly targeted way. However, there are still many unanswered questions that need 
exploring before the full potential of these strategies can be understood. 
In the first part of the study, we introduced a minimally invasive strategy for 
delivering protein therapeutics into the cornea. In this work, we showed that highly 
targeted intracorneal delivery of bevacizumab using a coated microneedle allows 
dramatic dose sparing compared to subconjunctival and topical delivery in an injury-
induced neovascularization model. The further studies are required to test the capability 
of delivering other therapeutics with different properties and formulations into 
intrastromal space of the cornea. Experiments should be designed to understand the 
relationship between different properties of molecules and pharmacokinetics of 
intrastromal injection. In addition, further studies to examine how the changes in 
formulations could influence the pharmacokinetics within the intrastromal space. For 
example, lipophilic drugs, such as steroids, may have prolonged residence times because 
of their low solubility in aqueous environments. In addition, formulation changes could 
be used to control diffusion of a molecule within the intracorneal space. In addition, 
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biodegradable particles with encapsulated drugs need to be evaluated within the 
intracorneal space to demonstrate sustained release. Understanding the diffusion of the 
drugs in the intraocular tissues as a function of properties of a molecule will help 
determine the potential of the intracorneal delivery.  
There are many hurdles that we have to overcome for this technology to be 
available for treating corneal neovascularization in the clinic. Even before starting human 
clinical trials, there are few things that we have to address. First, a viable product should 
have a long shelf life. Therefore, long-term stability of bevacizumab in a dried state needs 
be studied. Optimum parameters that impact the stability of bevacizumab must be studied 
to create a suitable packaging environment for coated microneedles. Second, a new pen-
like device to hold the microneedle and to make the insertion procedure easier has to be 
designed.  
For the second part of the study, we developed novel formulations to immobilize 
or to enhance the spreading of injected polymeric particles. Future work needs to focus 
on understanding the mechanism of the immobilization and the spreading of the 
polymeric particles by observing the movement of excipient formulations. Moreover, 
further experiments are needed to understand the pharmacokinetics of described 
suprachoroidal targeting and how different properties of injected drug impact the 
biodistribution. In addition, biodegradable particles with encapsulated drugs need to be 
evaluated within the suprachoroidal space to demonstrate sustained release.  
In order for this technology to be available in clinic, there are many additional 
hurles that we have to overcome. First, the anatomical differences in the suprachoroidal 
space of different species must be studied before starting the human clinical trial. It is 
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possible that physiological barriers might exist inside the suprachoroidal space to block 
the spreading of injected steroid particles. Second, often times, posterior and pan-uveitis 
involve inflammation in the layer of both choroid and retina. Further studies have to be 
carried out to determine if suprachoroidal delivery alone is capable of reducing 
inflammation in both choroid and retina. If suprachoroidal delivery alone cannot reduce 
retinal inflammation, the minimal intravitreal dose that could be used in conjunction with 
suprachoroidal delivery should be studied. 
In the third part of the study, we showed highly targeted delivery of anti-
glaucoma drugs to the supraciliary space using a hollow microneedle allowed dramatic 
dose sparing of the drug compared to topical eye drops. Future work needs to focus on 
understanding the pharmacokinetics of supraciliary targeting and how different properties 
of injected drugs impact the biodistribution. In addition, biodegradable particles with 
encapsulated drugs need to be evaluated within the supraciliary space to demonstrate 
sustained release. We believe this study can contribute to the development of novel 
therapies for glaucoma.  
In order for this technology to be available in the clinic, there are many additional 
hurdles that we have to overcome. We still know very little about safety of injected 
biodegradable particles in the suprachroidal space. Further safety studies are required to 
see if polymeric formulation cause adverse events. One critical drawback of delivering 
controlled release formulations is that we cannot stop the medication in case adverse 
events occurs in a patient. Therefore it is crucial to make sure that patients are free from 
adverse events before administering controlled release formulations.  
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In the fourth and final part of the study, we showed particle-stabilized high-
density emulsion droplets (PEDs) could be used to enhance targeting of various locations 
in the eye via suprachoroidal space injection. Future work is needed to optimize the 
injection volume, PED concentration, and polymeric particle sizes for better mobility or 
targeting inside the suprachoroidal space. Experiments should be designed to understand 
how surface properties of PEDs change the interactions between the tissue and PEDs 
within the suprachoroidal space. Future work also needs to focus on understanding the 
intraocular pharmacokinetics of drug loaded PEDs. In addition, pharmacodynamics study 
to demonstrate dose sparing of this highly targeted delivery method will help determine 
the potential that these injections have on treating eye diseases.  
There are many additional hurdles that we need to overcome for this technology 
to be available for treating age-related macular degeneration in the clinic. First, the 
anatomical differences in the suprachoroidal space of different species must be studied 
before starting the clinical trials. It is possible that physiological barriers might exist 
inside the suprachoroidal space to block the spreading of injected PEDs. Second, there 
are some additional concerns with the formulation of PEDs. Biodegradable particles, and 
aqueous formulation too, have to be in a separate container because particles will dissolve 
inside the aqueous formulation during storage. Because particles cannot be stored in 
aqueous formulation, additional formulation studies are required to keep dried form of 
PEDs to be separated from aqueous formulation. 
Overall, these studies offer exciting opportunities to target various locations 
within the eye enabled by microneedle technology. Studies in this thesis demonstrate and 
show many advantages of delivering drugs within specific locations of the eye in a 
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minimally invasive way. A successful treatment requires effective combination of a 
pharmacological therapy and a delivery method. Recent advancement in biotechnology is 
allowing more macromolecular therapeutics to be in the market but conventional delivery 
methods are not efficient in delivering macromolecules to the targeted site of action and 
achieve full potential of the developed pharmacological therapies. Microneedle-based 









A.1. Mathematical Modeling And In Vivo Imaging Of Bevacizumab (Chapter 3) 
Diffusion of immunoglobulin G (IgG) in stroma was modeled by modifying the 
previous work in literature[210], which combines an expression for 2-dimensional radial 
diffusion from a bolus source in cylindrical coordinates with a term to account for loss in 
the z dimension across epithelium and endothelium (k) to describe concentration, C, of a 
solute molecule in stroma. Following equation was used to evaluate the concentration of 
injected bevacizumab around the delivery site as a function of time. An amount, M0, of 
protein is injected at time 0, and it can be considered diffusing radially in the stroma. 
After time, t, the concentration of protein is given by following equation. Where D is 
effective solute diffusivity in stroma, r is distance from insertion site, a is radius of 
insertion bolus, and u and k are constants. Analytical solution is given by Crank [211]. 
Mathematical modeling of drug diffusion after intrastromal delivery will predict 
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Since our experimental measurements were fluorescent signal intensity in a fixed 
region of interest (ROI) over time (t), the above equation can be integrated with respect to 
distance R from the center of the insertion site to yield the following equation. Diffusivity 
and the endothelium diffusion constant was obtained from literature [210]. Quantitative 
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measurements of the pharmacokinetic of labeled bevacizumab in stroma will be 
measured periodically for up to 8 days using in vivo florescence measurement. Image 
analysis was calibrated against coating formulation with known concentrations. The 
dynamic range we were able to obtain was 66.64 ~0.02 mg/mL. The concentration of be 
bevacizumab was verified using ELISA. Insertion was made on the superior side of the 
eye using 4 microneedles 1mm away from the limbus.  
 














                     (2) 
 
Prior to insertion and imaging procedure, rabbits were anesthetized with ketamine 
(6 mg/kg) and xylazine (4 mg/kg) and acepromazine (0.25 mg/kg) subcutaneously. Eyes 
were kept open using lid speculum for the whole duration of the imaging procedures. The 
fluorescent signal intensity in the rabbits was measured on a Caliper Xenogen Lumina In 
Vivo Imaging System (IVIS) at 0, 2, and 4 days post insertion. Animals were imaged at 
745 nm excitation, 780 nm emission and 1 second exposure time. Fluorescence intensity 
was measured as background-subtracted average efficiency within a fixed region of interest 
(ROI) centered on the insertion site.  
 
A.1.1. Intracorneal Bevacizumab Diffusion Modeling 
We sought to better understand the diffusion of the IgG molecules inside the 
corneal stoma after microneedle insertion using mathematical model. Aside from the 
diffusion of molecules radially, molecules can diffuse through the endothelium and 
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epithelium.  The loss through the epithelium could be significant due to the hole created 
by inserting microneedle into the corneal stroma. The loss through the both endothelium 
and epithelium are represented by the unknown constant (k). Furthermore, there could be 
a variation in the radius of the instantaneous source (a) because the microneedle was 
inserted into the cornea not perpendicular but at an angle.  
Theoretical model was fitted with given initial value and by varying the value of k 
and a using least square analysis method. An exponential decline in signal intensity of the 
labeled bevacizumab delivery was observed, with 97% of the signal lost by 4 days after 
the delivery. The experimental and theoretical value of labeled bevacizumab was 
compared and showed decent fit. The percent difference between experimental and 
theoretical values were in as low as 0.29 % and as high as 100 %. The obtained value of a 
and k was 100 µm and 0.41 h-1, respectively. The rate of the loss through the endothelium 
was previously measured by Allensmith et al [212] to be 0.00104 h-1. The large 
difference between the two values indicates the significant loss through the hole what 
was made by the inserting the microneedle. In addition, sensitivity analysis showed a 
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